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CHAPTER I 
INTRODUCTION 
Impact of solid tumor metastasis to bone 
Cancer metastasis to bone is a common problem in patients with metastatic tumors 
such as breast, prostate, and lung cancers.  For example, it is estimated that 70% of patients 
with metastatic breast cancer and 90% of patients with metastatic prostate cancer will develop 
tumors in bone (1), and while 5-year survival rates remain high for breast tumors confined to 
the primary site, these rates decline by a staggering 62% when patients develop distant 
metastases (2009, ACS Cancer Facts & Figures).  Once tumors have established in bone they 
disrupt normal bone remodeling that can result in an excess of poorly formed bone 
(osteoblastic-prostate) or the destruction of bone (osteolytic-breast and lung), though most 
patients display a mixture of both.  This disruption in normal bone homeostasis increases 
patient risk of developing fractures, bone pain, spinal cord compression, and hypercalcemia (2), 
resulting in a dramatic decrease in quality of life and poor clinical outcome.  Hypercalcemia, 
which can lead to liver failure, coma and death (3), is of particular concern in these patients due 
to the extent of calcium resorption throughout the skeleton.  The current standard of care for 
these patients is bisphosphonate treatment, which may cause such negative side effects as 
osteonecrosis of the jaw (4) and increased atypical fractures (5), emphasizing the importance of 
finding new therapeutic targets to treat bone metastases.  Importantly, once tumor cells 
metastasize to bone they become incurable, and while treatments have improved, the patients 
will eventually die from the disease.  
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Normal bone remodeling 
When breast tumor cells metastasize to bone, they disrupt normal bone remodeling, or 
the coupling of osteoblast-induced bone formation and osteoclast-mediated bone resorption.  
Bone remodeling is a continuous process that occurs over the entire skeleton and throughout a 
person’s lifetime to regulate bone homeostasis (6).  Although the exact mechanisms that initiate 
normal bone remodeling are unknown, it has been proposed that osteoclast precursors are 
recruited from the bone marrow or capillaries to initiate bone turnover, where they 
differentiate into mature osteoclasts and simultaneously begin resorbing bone and recruiting 
osteoblast precursors (osteoprogenitors) (6).  Once differentiated, osteoblasts replace the 
resorbed section of bone with new matrix, and mineralization completes the process (6).  
Osteoblasts 
There are a number of signaling pathways which drive pluripotent mesenchymal stem 
cells within the bone marrow to differentiate into osteoblasts, including Hedgehog (Hh), bone 
morphogenetic protein (Bmp), transforming growth factor-beta (Tgf-β), parathyroid hormone-
related protein (PTHrP) and Wnt signaling, which drive osteoblast maturation at various stages.  
Osteoblasts (bone forming cells) and chondrocytes (cartilage forming cells), share a common 
osteo-chondrogenic precursor.  This precursor cell shifts toward the osteoblast lineage when 
osteoblast differentiation factors are turned on, such as Runx2, which is considered a “master 
switch” of osteoblast differentiation, since Runx2-/- mice lack osteoblasts throughout the 
skeleton (7), a phenotype that has yet to be matched when other factors driving differentiation 
are knocked out.   
Indian hedgehog (Ihh) signaling has been identified as a major component of osteoblast 
differentiation in endochondral bone formation, since Ihh knockout mice lack osteoblasts in the 
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long bones (8, 9).  Tgf-β and Bmps, which are members of the Tgf-β superfamily, signal through 
Smad proteins.  Bmps are required for skeletal formation during development, and conditional 
knockout mice have shown that these mice have skeletal abnormalities (10).  Tgf-β signaling in 
bone is a more complicated story, which mimics its biphasic role in cancer where Tgf-β is 
protective against metastasis at the primary site, but promotes invasion and metastasis in later 
stages of disease.  Tgf-β signaling through activation of Smad3 has been shown to enhance bone 
mineralization (11), but others have found that Tgf-β inhibition using small molecule inhibitors 
results in enhanced bone formation (12, 13).  In addition to Tgf-β signaling, PTHrP is critical for 
bone formation, and PTHrP knockout mice experience a postnatal death (14) and transgenic 
mice display shortened limbs due to defects in the growth plate (15).  Wnt signaling defects 
have been widely associated with skeletal defects and alterations in osteoblast differentiation.  
Specifically, β-catenin has been identified as an important component in driving osteo-
chondroprogenitor cells away from the chondrocyte lineage and toward osteoblast 
differentiation (16, 17), and mutations in the Wnt signaling receptor low density lipoprotein 
receptor-related protein 5 (LRP5) are associated with bone disease resulting in high or low bone 
mass (18-20).  Importantly, most of the signaling pathways that regulate osteoblast 
differentiation and maturation form multiple signaling loops and crosstalk extensively, which 
highlights the frustration and complexity of targeting a single signaling pathway in bone disease. 
Osteoclasts 
 Osteoclasts arise from monocytic precursors stimulated by two separate factors, the 
ligand for receptor activator of NFκB (RANKL) and macrophage-colony stimulating factor (M-
CSF), which are sufficient to drive osteoclastogenesis.  Another important factor regulating 
osteoclast formation is osteoprotegerin (OPG), which is a high affinity decoy receptor for RANKL 
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secreted by osteoblasts along with RANKL.  There are a number of cytokines which have been 
identified as regulators of osteoclasts such as interferon γ (IFNγ), but much of the data is in 
conflict with previously published studies or those conducted in humans (21-23).  1,25-
dihydroxyvitamin D regulation of the osteoclast  is slightly more straight-forward, in that vitamin 
D up-regulates RANKL mRNA expression and inhibits OPG and PTH production (24, 25), but 
studies in humans indicate that high levels of vitamin D are osteolytic.  It is also now evident 
that estrogen (E2) affects T cell secretion of tumor necrosis factor (TNF) and RANKL, which is a 
member of the TNF superfamily (23).   
Breast tumor cells can disrupt the tightly regulated process of osteoblast and osteoclast 
coupling by antagonizing differentiation and activity on multiple levels and at numerous skeletal 
locations, which may cause the normal bone remodeling process to preferentially favor bone 
resorption or bone formation.  Although patients may have both increased bone formation 
(osteoblastic) and increased bone resorption (osteolytic) at different sites of skeletal metastasis, 
breast cancer patients most frequently present with primarily osteolytic metastases which result 
from tumor cell activation of osteoclasts by both direct and indirect mechanisms.   
Concept of the vicious cycle 
Dr. Gregory Mundy coined the term “vicious cycle” approximately 20 years ago to refer 
to the important interactions between tumor cells and the bone micro-environment.  In this 
model, factors from the tumor stimulate osteoclast-mediated bone destruction, which results in 
growth factors being released from the bone to stimulate further growth of the tumor cells and 
thus the production of more tumor-derived osteolytic factors (Figure 1) (26).   
While the concept is overly simplified in order to illustrate the hypothesis, the vicious 
cycle has held up well over the past 20 years with the mechanistic and clinical data collected.   
  
Figure 1.  The vicious cycle of bone destruction.
metastasize to bone may secrete osteolytic factors which signal to osteoblasts 
to up-regulate expression of RANK.  This results in increased 
osteoclastogenesis
mineralized bone m
micro-environment
further secretion of osteolytic factors.
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This is especially true in studies using osteoclast inhibitors, such as bisphosphonates. These 
studies have demonstrated that inhibiting the bone resorption phase also reduces the tumor 
burden.  While there is disagreement in the field as to whether bisphosphonates directly inhibit 
tumor cell growth, it is clear that inhibiting bone resorption inhibits tumor cell growth (4).  
Furthermore, inhibiting tumor-produced factors such as PTHrP inhibits bone destruction and 
further tumor growth (27, 28).    
Our notion of the vicious cycle continues to emerge as we learn more about the 
interactions between tumor cells and the bone.  It has become clear that many factors within 
the bone micro-environment interact with the tumor cells, and that these interactions are far 
more complicated than the original vicious cycle model alone can explain.    For example, we 
now know that tumor cells can closely interact with osteoblasts (29-31), bone stroma (32), and 
immune cells (33, 34).   
Molecular mechanisms of bone metastasis (osteolytic) 
Breast and lung tumor metastasis to bone frequently results in significant osteolytic 
bone destruction through activation of osteoclasts in bone.  Tumor cells which establish in bone 
up-regulate the expression and secretion of osteolytic factors which stimulate RANKL expression 
in osteoblasts and results in osteoclast activation through RANKL/RANK binding.  PTHrP has 
been identified as a major osteolytic factor produced by tumor cells to activate bone destruction 
(26, 35), and our group has identified the developmental transcription factor Gli2, among other 
factors, as a key regulator of PTHrP transcription and secretion (36).   
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PTHrP discovery 
PTHrP was originally identified as a novel mediator of humoral hypercalcemia of 
malignancy (HHM) when it was isolated from a human lung cancer cell line (37).  The initial 
discovery of PTHrP identified a pre-pro-peptide and mature protein with homology to human 
PTH at the N-terminal end.  However, the C-terminus differed significantly from PTH, suggesting 
an evolutionary mechanism of gene duplication.  Indeed, the chromosomes on which PTH and 
PTHrP reside, chromosome 11 and 12, respectively, are evolutionarily related, and the authors 
believe that the more complicated primary structure of PTHrP suggests it is the original gene 
(37-41).  In addition to its numerous introns and exons, PTHrP possesses three separate 
promoters which produce three isoforms of PTHrP (1-139),( 1-141), and (1-173) (42, 43), which 
all have similar function, although isoform (1-139) appears to be the most potent inducer of 
osteolysis in a mouse model of breast cancer metastasis to bone (44).  It should be noted that 
the gene expression assays utilized to complete this dissertation detect all three isoforms of 
PTHrP. All isoforms of PTHrP, as well as PTH, function through binding and activation of the G-
protein coupled receptor PTH receptor 1 (PTHR1). 
Shortly after the identification of PTHrP, immunohistochemical analyses of breast 
cancer patients found that PTHrP was present in 60% of tumors but not in matched normal 
breast tissue (45) and correlated positively with patient prognosis.  Further analyses revealed 
that PTHrP was expressed in 92% of breast tumors in bone, compared with only 17% of breast 
tumors in non-bone sites (46).  Taken together, these data indicated that PTHrP expression at 
the primary site is a positive prognostic indicator and negatively correlates with PTHrP 
expression in breast tumors in bone, where it may create a favorable niche for tumor growth.  A 
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number of clinical studies have since confirmed the initial observations of differential PTHrP 
expression in cancer patients (47-50). 
PTHrP in the growth plate 
In addition to its role in breast cancer bone metastasis, PTHrP plays a significant role in 
bone formation through osteoblast regulation, as previously discussed, and growth plate 
chondrogensis downstream of Ihh signaling (51). As previously discussed, PTHrP knockdown 
results in shortened limbs and postnatal death (14), which is in large part due to altered 
chondrocyte differentiation.  Immature proliferating chondrocytes normally secrete PTHrP in 
response to Ihh derived from differentiating hypertrophic chondrocytes, which express the 
PTHrP receptor PTHR1.  PTHrP, having been stimulated by Ihh signaling, acts back on the 
proliferating and prehypertrophic cells to slow their differentiation into hypertrophic cells, 
creating a negative feedback loop (52).  Thus, knockdown of PTHrP results in more chondrocyte 
hypertrophy and less cartilage formation.    
PTHrP in mammary development 
In relation to its involvement in bone, a significant role for PTHrP has been discovered in 
mammary development and lactation.  PTHrP has been found both to be expressed in the 
lactating breast (53) and secreted into breast milk (54), and it is a critical component of 
mammary mesenchyme differentiation.  Specifically, epithelial cells within the mammary bud 
express PTHrP, which signals via the PTHR1 to the surrounding mesenchyme that is responsible 
for ductal outgrowth (55).  Accordingly, PTHrP knockdown mice lack mammary glands due to 
interrupted PTHrP/PTHR1 signaling (56).  Interestingly, PTHrP that is secreted into breast milk is 
believed to promote bone resorption in order to supply enough calcium for milk production, as 
evidenced by decreased bone turnover in mice with mammary specific knockdown of PTHrP 
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(57).  PTHrP-stimulated resorption is regulated through expression of the calcium-sensing 
receptor (CaR), which is also expressed in the lactating breast and inhibits PTHrP secretion in a 
feedback mechanism (58).     
Gli2 signaling 
PTHrP is regulated through a number of mechanisms, some of which include Gli2 and 
Tgf-β effects on PTHrP expression, activity, and stability.  Recent studies have pinpointed the Hh 
transcription factor GLI2 as a major regulator of PTHrP.  Specifically, chondrocytes in bones 
harvested from GLI2 embryonic lethal knockout mice showed decreased expression of Ihh, 
Patched (Ptch) and PTHrP (59).  Based on these data and the involvement of PTHrP in tumor-
induced osteolysis, the relationship between Gli2 and PTHrP was further explored in osteolytic 
and non-osteolytic breast cancer models (36).  Interestingly, Gli2 was found to be up-regulated 
in osteolytic breast cancer cells which expressed PTHrP and metastasized to bone resulting in 
osteolytic lesions (36).  Gli2 is regulated in large part by the Hh signaling pathway during 
development, and Dennler and colleagues have shown that the GLI2 promoter in keratinocytes 
and hepatocellular carcinoma contains a Smad-binding element (SBE) and TCF-binding element 
(TBE), implicating Tgf-β and Wnt signaling as co-regulators of GLI2 transcription (60).  
Additionally, we have shown that Gli2 expression in osteolytic tumor cells is regulated by a 
number of factors independent of Hh signaling, such as Tgf-β (61).  Gli2 was found to be 
necessary for Tgf-β stimulation of PTHrP mRNA expression, and is therefore an excellent target 
in blocking osteolysis.  Gli2 blockade has indeed been successful in blocking osteolytic bone 
destruction in a genetic model (61), and studies are underway to inhibit Gli proteins through 
small molecules, such as the GANT compounds (62) and Excoecaria agallocha (E. agallocha) 
extracts from Japanese herbals (63).  The effectiveness of Gli2 blockade in decreasing osteolysis 
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introduces the possible involvement of Gli2 in metastasis; although there is currently no 
evidence to suggest that Gli2 regulates genes important for osteotropism (64), Tgf-β regulation 
of Gli2 opens up the possibility that Gli2 may still play a role in metastasis to bone.   
Canonical Hh signaling occurs through Hh ligand binding to the membrane receptor 
Patched (Ptch), which releases inhibition of a second membrane receptor, Smoothened (Smo).  
This release initiates a downstream signaling cascade resulting in translocation of the Gli family 
proteins to the nucleus, where they can initiate transcription (65).  Gli proteins have been 
demonstrated to be up-regulated in a number of tumor types, including medulloblastoma and 
those of the prostate, pancreas, and lung, suggesting that Gli may play an important role in 
tumorigenesis; however, the mechanisms resulting in Gli up-regulation can vary from 
inactivating mutations of Ptch to activating mutations of Smo or Suppressor of Fused (SuFu) 
(66).  
Since Gli proteins are up-regulated in tumors of different origins, a number of screens 
have been developed to identify Hh signaling inhibitors.  The most notable and widely-used of 
these inhibitors is cyclopamine, a potent Smo receptor antagonist reported to work in tumor 
models with varying levels of success (67, 68).  More recently, a cell-based screen by Lauth and 
colleagues uncovered two antagonists of Gli signaling, GANT58 and GANT61, which have been 
shown to inhibit prostate cancer cell growth in a subcutaneous prostate tumor model which also 
expresses PTHrP (62) and can inhibit activation of Hh target genes despite potential upstream 
mutations in the signaling pathway.  While the mechanism is unclear, these compounds are 
believed to block Gli1 translocation to the nucleus, and may therefore also block Gli2 since it is 
similar in structure to Gli1.  The success of Gli antagonists in primary xenograft tumor growth 
suggests that GANT molecules may also be beneficial in treating osteolytic bone metastases by 
11 
 
both blocking tumor-induced bone destruction and inhibiting cell growth.  Furthermore, the 
investigation of these small molecule inhibitors on tumor-induced bone disease may provide a 
novel therapeutic target for blocking osteolysis.   
Tgf-β signaling 
We and others have shown that Tgf-β impacts PTHrP expression both in vitro and in vivo 
(61, 69).  Specifically, MDA-MB-231 human osteolytic breast tumor cells made unresponsive to 
Tgf-β signaling through expression of a dominant negative TGF-β receptor type II (DNRII) 
showed a significant reduction in PTHrP secretion and exhibited significantly smaller osteolytic 
lesions in a mouse model of breast cancer metastasis to bone (69).  Accordingly, our data has 
shown that in addition to regulating PTHrP secretion, Tgf-β alters PTHrP mRNA expression and, 
furthermore, that its effects are mediated through Gli2 (61).  Our group has also found that Tgf-
β inhibition using a neutralizing antibody against the Tgf-β ligands blocks tumor-induced 
osteolysis and reduces PTHrP activity and mRNA expression, although these data are not yet 
published (Biswas et al., submitted). 
Tgf-β and mRNA stability 
In addition to regulating PTHrP mRNA expression and secretion, Tgf-β signaling is known 
to play a significant role in messenger RNA stabilization and turnover (70).  Newly transcribed 
RNA is subjected to a number of post-transcriptional modifications before leaving the nucleus, 
such as 5’ methyl-capping, splicing, cleavage, and polyadenylation to prevent proteasomal 
degradation (71), where the modified transcript then enters the cytoplasm and interacts with 
mRNA binding proteins, including Tgf-β.   
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Regulators of PTHrP mRNA stability include 1,25 Dihydroxyvitamin D3, the hormonally 
active form of Vitamin D, which decreases both PTHrP mRNA expression and stabilization 
through a vitamin D response element in prostate cancer (72), and von Hippel-Lindau tumor 
suppressor protein, which negatively regulates PTHrP mRNA stability through the RNA binding 
protein HuR, which is also known to bind and stabilize VEGF, Tgf-α, and Tgf-β (73, 74).  Previous 
reports have suggested that Tgf-β signaling may play a crucial role in regulating PTHrP mRNA 
stability (75-77); however, there are conflicting published data concerning Tgf-β stabilization of 
PTHrP transcript (78).    For example, when SCC2/88 cells were treated with Tgf-β1, PTHrP 
production was increased, but there was no effect on mRNA stability; however, when the 3’-UTR 
of PTHrP transcript was truncated, Tgf-β treatment stabilized the message due to decreased 
binding to the coding region (79, 80).  Conversely, when PTHrP mRNA stability was examined in 
keratinocytes following treatment with exogenous Tgf-β, PTHrP mRNA stability was significantly 
up-regulated (76).  Therefore, it is likely that Tgf-β effects on PTHrP message stability is highly 
dependent on the cell type being used and the precise processing of PTHrP in these cells.   
Wnt signaling 
 Deregulated Wnt signaling has been implicated in the pathogenesis of a number of 
different tumor types, including tumors of the breast and prostate.  However, there is little data 
on Wnt signaling in these tumor types once they have reached the bone marrow.  Conversely, 
Wnt signaling components, in particular Dkk1, have been identified as key regulators of Multiple 
Myeloma (MM)-induced bone disease.  MM is a malignancy of the plasma cells with significant 
bone involvement and osteolytic disease, resulting from a combination of suppressed bone 
formation and enhanced bone resorption.  Dkk1 inhibits Wnt signaling, which is important in 
osteoblast differentiation.  Studies have shown that inhibition of Dkk1 reduces tumor burden 
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and enhances bone formation in mouse models of MM (81).  In addition to Dkk1, secreted 
frizzled-related protein 2 (sFRP2) is produced by MM cells and blocks osteoblast differentiation 
(82).  Interestingly, very recent data has indicated that sFRP1, 2, 4 and 6 are also produced by 
MM cells, and that hypermethylation of their respective promoters frequently occurs in 
patients.  Indeed, this epigenetic regulation of sFPR2 occurs in up to 52.6% of patients with MM 
(83).  However, considering that up to 70% of MM patients have skeletal involvement and that 
Wnt signaling inhibition in mouse models results in increased bone formation (84), the dual 
roles of Wnt signaling in MM remains to be sorted out.  
Other osteolytic factors (MMPs, RANKL, IL-8, Runx2) 
PTHrP remains the most well studied of the osteolytic factors produced by bone 
metastatic tumor cells, but there are other molecules which contribute significantly to tumor-
induced bone destruction, such as RANKL, IL-8, Runx2, and the matrix metalloproteinases 
(MMPs).  Interleukin-8 (IL-8) expression in tumor cells has been shown to correlate with 
increased bone metastases in human breast cancer cells (85) and stimulate osteoclastogenesis 
independent of osteoprotegerin (OPG) (86) and RANKL (87).  Runx2, which is required for 
normal bone formation, is elevated in breast and prostate tumors and cells which metastasize to 
bone, and inhibition of Runx2 in breast tumor cells inhibits tumor-induced bone destruction 
(88).  This inhibition is in part due to alterations in MMP-9 signaling, which is downstream of 
Runx2, and is important for tumor cell invasive properties (89).  There is also evidence to 
support significant involvement of MMPs in regulating tumor-bone interactions.  For example, 
MMP-7 has been shown to enhance osteolysis through solubilization of osteoblast-derived 
RANKL in the PC-3 prostate cancer model of bone destruction (90), and was found to play a 
similar role in breast tumor-induced osteolysis (91). 
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Molecular mechanisms of bone metastasis (osteoblastic) 
Some cancers such as prostate, and less frequently breast, induce osteoblastic bone 
disease upon metastasis to bone.  The mechanism driving the formation of osteoblastic lesions 
is unclear, but bone resorptive markers are often elevated in these patients, suggesting that 
osteoclast activation may still be necessary for the formation of osteoblastic lesions.  Similar to 
patients with primarily osteolytic bone metastases, prostate cancer patients frequently present 
with mixed lesions throughout the skeleton.  It is believed that at least in some cases, 
osteoblastic metastases begin with a heavy resorption component then switch to blastic lesions.  
This is further supported by the successful use of bisphosphonates, which inhibit osteoclast 
activity, in the treatment of prostatic bone metastases and associated bone pain (92). 
The molecular mechanisms which stimulate bone formation in osteoblastic metastases 
remain largely undiscovered, but there is evidence to suggest that endothelin-1 (ET-1) and the 
Wnt signaling pathway make significant contributions.   Dkk1 is a downstream target and 
inhibitor of the Wnt signaling pathway, and has been shown to inhibit prostate tumor-induced 
osteoblastic metastases when over-expressed in prostatic tumor cells by inhibiting TCF activity 
in osteoblast precursors (93); conversely, Dkk1 has been identified as a mediator of tumor-
derived ET-1-induced bone formation (94), suggesting an autocrine loop in which Dkk1 and ET-1 
up-regulate one another.  Differences here may be attributable to cell-line specificity, since 
Thudi et al utilized ACE-1 prostate tumor cells, and Clines et al did not test his model in tumor 
cells.  More data is needed to determine the extent of ET-1 regulation of Wnt signaling.  
Tumor micro-environment regulation of bone disease 
Certain tumor types rely heavily on autocrine signaling, but cancer cells are not as 
autonomous as once thought.  In recent years, increasing emphasis has been placed on tumor 
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micro-environment influence on tumor cell behavior and the interactions between tumor cells 
and the stroma in particular.   It has become evident that the micro-environment plays a 
tremendous role in both promoting and hindering tumor progression at different sites of the 
disease.  While the host micro-environment significantly impacts tumor cell evolution, cancer 
cells may also influence host cells at the site of metastasis in addition to systemic alterations.  
This is particularly evident in the vicious cycle of bone destruction which requires extensive 
interactions and complex signaling between tumor cells, bone, and the bone marrow stroma.  
While there are numerous interactions occurring within the bone micro-environment, some of 
the micro-environmental factors which have been identified as significant mediators of tumor 
host interactions include matrix stiffness, the reactive stroma surrounding the tumor, Tgf-β, Wnt 
signaling, and Ephrins.      
Stiffness and the extracellular matrix 
The extracellular matrix (ECM) has long been thought of as a structural scaffold on 
which tumor cells could rely on for support, but there is now substantial evidence to suggest 
that breast tumor cells modify their behavior in response to ECM signaling and the changing 
stiffness of the ECM at the primary site (95).  In the primary site of breast cancer, tumor 
progression has been connected with increased collagen crosslinking as well as integrin 
activation (96), and our group has shown that the rigidity of bone modulates tumor cell gene 
expression in a ROCK-dependent mechanism (97).  These data show that osteolytic tumor cells 
detect the rigidity of the substrate upon which they are plated, and up-regulate gene expression 
as rigidity increases (97).   These are key data in identifying the point at which tumor cells “turn 
on” PTHrP expression, since they demonstrate that osteolytic tumor cells require stiffness on 
the order of magnitude of bone in order to secrete biologically significant amounts of PTHrP.  
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The response of tumor cells to the physical micro-environment is complex and still actively being 
explored. 
Stroma and fibroblasts 
Much of the signaling which modulates tumor cell behavior in bone originates from the 
surrounding stroma.  The contribution of the reactive stroma in tumor cell evolution has been 
well established, particularly in prostate cancer through studies conducted by the Cunha and 
Hayward groups (98, 99), but the impact of bone stroma in particular on tumor cell behavior is 
becoming appreciated.  Most of the published data supports a significant role for bone-derived 
growth factors and chemokines (e.g. Tgf-β, SDF-1/CXCR4) (32, 100, 101), and an emerging role 
for immune cells such as MDSCs.  It is well established that stromal derived factor-1 (SDF-
1/CXCL12) is involved in tumor cell homing to bone (102), where it has been shown that bone 
metastatic breast cancer cells express elevated levels of the SDF-1 receptor CXCR4 (64, 103), and 
conditioned media from primary human bone marrow contains CXCL12 (103), which presumably 
promotes metastasis to bone.  Indeed, tumor cell migration can be blocked when the 
CXCR4/CXCL12 interactions are blocked by a neutralizing antibody against CXCR4 (103). 
Fibroblasts isolated from common sites of breast cancer metastasis (e.g lung, liver and 
bone) have also been shown to promote tumor cell growth more effectively than skin fibroblasts 
and do so in an IL-6-dependent manner (104), which strongly supports the idea of the pre-
metastatic niche.  These data are further supported by data from Bob Weinberg’s group, 
showing that bone marrow-derived mesenchymal stem cells increase the aggressiveness of 
weakly metastatic breast carcinoma cells (105).  Interestingly, fibroblasts appear to have the 
largest impact on breast cancer cell lines which are estrogen receptor-alpha (ER-α) positive 
(106), despite most breast cancer cells which metastasize to bone being ER negative.  This is 
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suggestive of distinctive and separate properties of fibroblasts in the primary site of disease and 
the bone marrow.  Accordingly, there is evidence that stromelysin-3, which facilitates tumor cell 
metastasis, is induced by Tgf-β in fibroblasts to promote tumor cell homing to the bone (107). 
Tgf-β signaling 
Tgf-β signaling is known to regulate such cell autonomous events as proliferation, 
migration, apoptosis, and tumor invasion (108), and has been shown to directly promote tumor 
cell growth in bone following release from the mineralized bone matrix (26).  Interestingly, these 
same processes are controlled during development in part by the Wnt signaling pathway (109), 
which has been identified as an important stromal component in metastatic prostate cancer 
(110).  Convergence of Tgf-β and Wnt signaling has been repeatedly demonstrated at the 
transcriptional level on the Gli proteins, which are downstream of the Hh signaling pathway 
during development. Previous reports have indicated that Wnt signaling can both regulate and 
be regulated by Gli proteins (111), although most publications place Hh signaling upstream of 
Wnt during development (112, 113). Likewise, Hh and Tgf-β signaling have been reported to 
crosstalk (108), and our group as well as others has reported that GLI2 transcription is regulated 
at least in part by Tgf-β signaling through Smads  (61, 114), indicating the importance of this 
crosstalk for regulating bone destruction. 
Tgf-β signaling involves three separate isoforms (Tgf-β1, 2 and 3) and two distinct 
serine/threonine kinase receptors, type I Tgf-β receptors (TβR-I) and type II Tgf-β receptors 
(TβR-II).  The signaling cascade initiates when Tgf-β1 ligand binds the TβR-II, and TβR-I is then 
recruited to the complex.  TβR-II phosphorylates TβR-I, which in turn phosphorylates and 
activates the Smad2 and Smad3 molecules.  These activated Smads then bind Smad4, which 
facilitates nuclear translocation and activation of transcriptional targets (70).   
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Canonical Wnt signaling 
Human osteolytic MDA-MB-231 breast cancer cells, which are frequently used as a 
model of breast cancer metastasis to bone when inoculated by cardiac injection, are both Tgf-β 
responsive and active Wnt signalers.  Canonical Wnt signaling is activated when one or more 
Wnt ligands bind to the cell surface receptors frizzled (Fz) and low-density lipoprotein receptor-
related protein 5 or 6 (Lrp5/6) and trigger a downstream signaling cascade.  In the absence of 
signal, disheveled (Dsh), Axin, tumor suppressor adenomatous polyposis coli (APC) and glycogen 
synthesis kinase-3-β (GSK3-β) complex together in the cytoplasm, which facilitates GSK3-β and 
casein kinase 1 (CK1) phosphorylation of β-catenin and its subsequent proteasomal degradation 
(115).  Once Wnt signaling is turned on, Axin is recruited to Lrp5/6 at the cell membrane and the 
Dsh-Axin-APC-GSK3-β complex is dispersed, causing β-catenin stabilization and translocation to 
the nucleus to activate the transcription factors T-cell factor (TCF)and lymphoid enhancer factor 
(LEF) and initiate transcription (115, 116).   
Aberrant Wnt signaling has been implicated in a number of tumor types, including 
breast cancer, but genetic mutations which result in Wnt activation are rarely found in breast 
cancer patients (117).  Conversely, β-catenin stabilization is often found in breast cancer, and 
still results in activation of Wnt target genes (117).  There are a number of genetic mouse 
models which result in Wnt activation and/or β-catenin stabilization.  For example, the MMTV-
LTR model, which drives the expression of activated β-catenin in the mouse mammary gland, 
results in the development of mammary carcinoma similar to tumors observed in MMTV-Wnt 
mice (118).  More recently, Wnt signaling has been identified as a key regulator of cancer stem 
cell proliferation, making it a promising target in breast cancer therapy (119).  
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Importantly, Wnt signaling plays a significant protective role in bone homeostasis.  
Mouse genetic models in particular have demonstrated its importance, showing that LRP5-/- 
mice exhibit a low bone mass phenotype and decreased pre-osteoblast proliferation (120).  Even 
more valuable than the mouse genetic studies are the clinical data documenting patients with 
LRP5 activating mutations resulting in a high bone-mass phenotype and enhanced osteoblast 
proliferation (18, 19).  These phenotypes are likely due to alterations in normal Wnt signaling, 
since it has been shown that canonical Wnt signaling also up-regulates osteoblast production of 
OPG, a decoy receptor for RANKL, and down-regulates RANKL, indirectly affecting 
osteoclastogenesis (121).  Indeed, Wnt signaling activation through APC inactivation results in 
increased bone formation and a dramatic reduction in osteoclasts (122).  Further studies have 
shown that Bmp2 promotes new bone formation in part by targeting alkaline phosphatase (ALP) 
and activating a Wnt signaling autocrine loop in pre-osteoblasts (123), and Bmp2 crosstalks with 
Wnt signaling to promote osteoblast differentiation by stimulating LRP5 expression and 
inhibiting β-TRCP, the ubiquitin ligase which targets β-catenin for degradation (124).  Canonical 
Wnt signaling has also been shown to target ALP in the presence of Bmp4 (125), as well as up-
regulate Runx2 expression and activity, which are critical for osteoblast differentiation and 
normal skeletal development (126).   
Non-canonical Wnt signaling 
The non-canonical Wnt signaling pathway, which can be broken down into several 
branches including the Planar Cell Polarity and Wnt/Ca2+ pathways, signals through Fz 
independent of Lrp5/6 and leads to activation of Dsh.  In the Planar Cell Polarity pathway, Dsh 
activates the small GTPases Rho and Rac downstream, which can activate Rho kinase (ROCK) and 
myosin to mediate effects on the actin cytoskeleton.  The Wnt/Ca2+ pathway is mediated 
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through trimeric G proteins and Dsh induction of Ca2+ release and activation of protein kinase C 
(PKC) and calcium/calmodulin-dependent kinase II (CamKII) (127).    Interestingly, the non-
canonical Wnt signaling pathway has also been identified as a positive regulator of bone 
formation.  For example, mice that are heterozygous for Wnt5a, a Wnt more commonly 
associated with non-canonical Wnt signaling activation, exhibit decreased bone mass and a 
reduction in osteoblast number.  This phenomenon appears to be tightly correlated with the 
extent of adipogenesis in the bone marrow, since Wnt5a+/- mice have elevated adipocyte 
numbers (128).  Further data indicate that Wnt5a represses PPARγ-induced adipogenesis in 
MSCs, tilting MSC differentiation toward Runx2 activation and osteoblastogenesis (128).  There 
is an overwhelming consensus that non-canonical Wnt signaling has a significant impact on bone 
formation, but much of the data supporting this has yet to be discovered.  Based on the current 
data, it appears that non-canonical Wnt signaling has a considerable effect on MSC fate and 
differentiation, which will likely have a significant effect on osteoblast biology. 
Ephrins 
Ephrin/Eph signaling has been identified as an important mediator in tumor promotion 
and angiogenesis, and preclinical studies have shown soluble EphB4 and EphB4 neutralizing 
antibody to be efficacious treatment in breast and prostate solid tumors (129, 130); however, 
disruption of Ephrin/Eph family signaling results in skeletal abnormalities and increased bone 
resorption by disrupting coupling between osteoblasts and osteoclasts which is required for 
normal bone modeling (131-133).  Further studies are needed to determine whether blockade 
of Ephrin/Eph signaling is detrimental in patients with potential bone metastatic disease, but it 
remains possible that Ephrin/Eph signaling, similar to Tgf-β, may play a biphasic role in tumor 
metastasis.   
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Immune cells 
Immune cells such as myeloid derived suppressor cells (MDSCs) have been implicated in 
tumor promotion and metastasis to distant organs (33), and more recently these cells have been 
suspected to play a key role in tumor metastasis to bone (134).  For example, it has been 
previously demonstrated that Gr-1+ CD11b+ MDSCs are capable of differentiating into 
osteoclasts in the 5T model of multiple myeloma (134), but further studies are needed to 
determine if this same potential exists in solid tumor metastasis to bone.  More recent data 
examining CD8+ T cells in breast tumor metastasis to bone suggests that immune cells influence 
tumor cell metastasis independent of tumor effects on bone, specifically showing that 
osteoclast activation of T cells reduces tumor burden but increases osteolysis (135).  As 
indicated by Fowler et al, the B cell population may be an important factor in the development 
of myeloma, since RAG-2-deficient mice which lack B cells develop 5T myeloma while nude 
mice, which have an intact B cell population, do not (136); however, it was also suggested that 
the elevated natural killer cell population in nude mice may contribute to this phenomenon.  
More studies are required to determine if these cell populations are significant in solid tumor 
metastases to bone, but the evidence from MDSCs and T cell promotion of osteolysis is 
compelling. 
Animal models for studying bone metastases 
Breast cancer models 
Some of the most common models of tumor-induced bone disease include tail vein 
(137-139), cardiac (36, 69, 140), and intratibial (141-143) inoculation of breast tumor cells. Many 
breast cancer models rely on cardiac injections, in which tumor cells are inoculated directly into 
the left cardiac ventricle. This allows for tumor cells to disperse throughout the body, but 
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bypasses the direct blood flow to the lungs. Other tumor-bone models, such as the myeloma 
models, rely on tail vein injections, which for breast cancer cells result in large tumor burden 
and premature death due to lung metastases. In certain cases tumors are inoculated directly 
into the tibia. While not a model of metastasis, this approach is extremely important for 
prostate models which do not readily metastasize to bone when injected intravenously. In 
addition, for certain breast cancer models, intratibial injections can indicate how alterations in 
gene expression of a tumor cell alter tumor growth in bone separately from metastasis. While 
these models are the primary models available for the study of human metastasis to bone, the 
ideal models are those that spontaneously metastasize from the mammary fat pad. 
Unfortunately, there are currently no human tumors that metastasize from the fat pad in mouse 
models. There are mouse models, such as the 4T1/BalbC model, which can metastasize to bone 
from the primary site (144, 145), but this model lacks the clinical significance that can only be 
achieved through human metastasis models.  
Prostate cancer models 
Prostate models of bone metastasis are particularly challenging.  The only metastatic 
models available utilize PC-3 cells, which unlike most prostate tumors in patients are purely 
osteolytic.  Therefore, these cells are rarely used for tumor-bone models.  Instead the field 
mostly relies on orthotopic models developed by Leland Chung’s group from LNCaP C4-2 cells 
derived from a lymph node metastasis (146, 147) and numerous cell lines isolated by the 
Vessella group from their rapid autopsy program (148).  These cells can also be directly injected 
into bone, where they develop into strongly osteoblastic tumors.    
 
 
23 
 
Lung cancer models 
The most popular models of cancer metastasis to bone have traditionally focused on 
breast or prostate, primarily since these cancers tend to be the most prevalent in the 
population; however, a recent shift in the prevalence of lung cancer metastases to bone has 
stimulated the use of the RWGT2 model of lung carcinoma, which was generated by the Mundy 
group (149).  This surge can be largely attributed to advancements in the treatment of lung 
tumors at the primary site, which extends patient survival from the primary tumor, but appears 
to facilitate the opportunity for tumor cells to metastasize to bone.  The RWGT2 intracardiac 
model causes significant bone destruction, similar to the clinical disease.   
Conventional techniques for imaging tumor in bone 
 In order to fully investigate these animal models, numerous imaging techniques have 
been applied with most focusing on imaging either the tumor cells or changes in bone.  
Radiography using Faxitron analysis has been the central tool for researchers monitoring bone 
disease for over 20 years, but other techniques have recently developed that allow for more 
comprehensive analysis, which will be discussed in the next section. 
Radiography 
Faxitron (Faxitron X-Ray, LLC) first developed their imaging equipment as a tool for 
micro-radiography in the 1960s and became popular as a method to perform ex vivo 
radiography on patient samples at higher magnification (150).  This equipment was later applied 
to small animal imaging, where over the past 20 years it has maintained its status as the primary 
method for monitoring cancer bone disease in small animal models (151).  While this approach 
has been very successful, in our experience it is difficult to accurately view the entire skeleton, 
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and small, early stage lesions are undetectable by planar radiography at such low resolution 
(141).  However, Faxitron analysis has remained popular because it allows for inexpensive, fast, 
and reproducible imaging.  The relative low price of the equipment and limited prep of animals 
before imaging still makes it an ideal imaging technique.  Faxitron imaging is primarily 
performed now using digital formats which are used to calculate lesion number and lesion area 
using software from Metamorph (141).  While the analysis is relatively basic in comparison to 
new more complex imaging techniques, the analysis is quick and reliable (36, 152, 153). As new 
technologies emerge it is unlikely that Faxitron imaging will ever fully be replaced, since it is the 
only technology that allows many samples to be processed quickly. 
Histology 
Perhaps the most standard imaging technique for all cancer and bone studies is 
histology.  Histology allows for cellular detail that even new and advanced imaging techniques 
cannot give.  In bone and cancer studies, researchers usually embed specimens in paraffin and 
stain with Hematoxylin and Eosin (H+E) to detect tumor burden in bone and Tartrate-Resistant 
Acid Phosphatase (TRAP) to quantify the osteoclast population as a parameter of osteolytic 
bone disease.  H+E sections are also useful in determining bone volume and gross physiological 
features.  Plastic embedding is also frequently used, especially for fluorescent staining, but is not 
preferred in tumor-bone samples since the difference in density between the bone and tumor 
can make clean sectioning difficult.  
Various different programs are used to quantitatively measure tumor burden, 
parameters of bone, and perform cell counts.  The most popular are Metamorph (36, 141, 152, 
153) and Osteomeasure (136, 138, 154), which both rely on region of interest (ROI) analysis. 
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Both essentially perform the same analyses and their use mostly depends on availability and the 
preference of the investigator.  
Fluorescence and luminescence 
The development of fluorescent proteins for transfection into tumor cells in 1997 (155) 
has revolutionized tumor cell detection and has become one of the standard techniques for 
monitoring tumor growth in vivo in a high throughput and quantitative manner.  As with many 
cancer fields, green fluorescent protein (GFP) imaging became the standard method for imaging 
tumors in bone as it gave us the ability to follow tumor cell growth without sacrificing the animal 
or performing more expensive and time consuming techniques, such as positron emission 
tomography (PET) imaging.  For example, Oyajobi et al recently published GFP imaging 
techniques suitable for imaging myeloma in bone (153).  Our group also uses GFP imaging as a 
standard practice for monitoring tumor growth in bone.  This approach gives us the option of 
imaging weekly, where we normally begin to see tumors growing in bone after 2-3 weeks, but 
also allows us to perform post-mortem ex vivo imaging or immunohistochemistry on tissue 
sections.  
Due to problems with background fluorescence and low depth of field of the green 
wavelength, other fluorescent proteins have been developed with longer wavelengths.  The 
most popular of these are the red fluorescent protein (RFP) vectors.  However, in our and 
others’ experience, these proteins all are associated with increased cell death. 
There are numerous systems available to detect the fluorescent proteins, many of which 
are very affordable (156).  However, in our experience the Maestro technology (Cambridge 
Research and Instrumentation, Inc.) has been the best for imaging fluorescence in bone.  This 
system allows us to eliminate background and examine specific peaks of fluorescence.  This 
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ability also allows us to image multiple fluorescent colors/wavelengths at the same time.  
Furthermore, this system allows for basic ROI quantification.  In addition to in vivo imaging, the 
Nuance multi-label imaging system (CRi) can be performed ex vivo on frozen sections.  These 
images can be re-constructed into a 3D image and co-registered with other imaging modalities 
and histology (157). 
Although in our experience GFP imaging has been very beneficial and successful, we are 
still unable to detect tumors in bone earlier than 2 weeks, which we believe is a limit of the 
technology and not that the tumors are not present in bone by 2 weeks after cardiac injection.  
For this reason many groups have switched to bioluminescence imaging (158-161).  In this 
system, tumor cells are transfected with a luciferase vector which enzymatically cleaves the 
substrate D-luciferin.  Upon imaging, full length luciferin is injected into the mice and given time 
for cleavage to occur at in vivo sites of luciferase expression.  Luciferase imaging allows for the 
detection and quantification of smaller tumors.  While the detection limit of luciferase imaging 
is superior to GFP, we find that the luciferase image peaks to maximum saturation early in some 
cases, making longitudinal quantification of larger tumors difficult.  While luciferase imaging can 
detect tumors in bone earlier than GFP imaging, it still cannot detect very small tumors in bone.  
Furthermore, luciferase imaging can be more cumbersome and lacks definition to the bone 
region, which prevents more detailed analysis by histomorphometry.  We have found that there 
is a reduction in metastasis to bone in tumor cells expressing the luciferase vector, but the 
reason for this is unclear.  Unlike the fluorescent proteins, which can induce a T-cell response 
(162), luciferase expression is not known to induce an immune response or cause toxicity (163).  
Despite the drawbacks, this is the best option for many models.  This is especially true in 
prostate cancer and other models that rely on mice with hair, which interferes with the GFP 
signal.  The most common system for luciferase imaging is the IVIS system (Xenogen).  This 
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system is relatively easy to use and performs basic quantification and is available at many 
institutions.   Again, this makes luciferase imaging ideal for many laboratories. 
There are benefits and draw-backs to both GFP and luciferase.  We suggest that in 
systems where luciferase and/or GFP expression do not interfere with cell growth or metastasis, 
that both be used to obtain maximum information. GFP expression will allow for later analyses 
and more detailed ex vivo analyses, while luciferase will allow for early detection of relatively 
small numbers of tumor cells.  If they cannot be used together, than the investigator needs to 
determine which to use based on what information is most critical.  For example, if early 
detection in live animals is a necessity than luciferase is the better option. 
The limitations of these conventional imaging techniques and others has driven the field 
to develop novel imaging modalities that allow us to better explore tumor-induced bone disease 
by enhancing resolution, sensitivity and the ability to examine molecular mechanisms in vivo. 
Innovations in tumor-bone imaging (Figure 2) 
Near-infrared proteins and antibodies 
Because of their long wavelengths, proteins in the red and Near-infrared (NIR) 
wavelength can penetrate deeper into tissues, allowing better visibility of tumors in deeper 
tissues, such as within the bones.  One group developed mKatuska (emission=588), eqFP650 
(emission=650), and eqFP670 (emission=670) for the expression of far red/NIR (164), which they 
describe as having low toxicity.  While they have not been tested extensively, these proteins 
should have all the benefits of GFP.  However, because they are in the NIR range, tumors should 
be able to be visualized deeper in tissues, and importantly, since there is no background 
fluorescence at the NIR wavelengths, lower signals should be more easily detected (164).  
 Figure 2.  Emerging imaging techniques and their application in tumor
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-induced bone 
destruction. 
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Another promising application of the NIR wavelength has been the conjugation of NIR 
dyes with antibodies or small molecules.  In this case NIR-labeled drugs can be targeted to 
specific proteins, allowing researchers to monitor the expression of the protein of interest in live 
animals.  This technology has been applied to monitoring several proteins in different tumor 
models (165-167).  For example, one group imaged colon cancer tumors using a small molecule 
targeted to peripheral benzodiazepine receptor (PBR), a receptor that is up-regulated in late-
stage colon cancer. This technique allowed them to accurately, rapidly, and inexpensively detect 
colon cancer. This technology should be highly applicable to bone metastases and many other 
tumor types.  From our group’s pilot data, the NIR small molecules are highly visible in bone, 
and are likely to become a standard imaging approach in the future. 
NIR imaging relies on much of the same equipment required for standard GFP imaging 
provided that the proper filters are available.  Otherwise, several companies have developed 
stand-alone systems for imaging and image analysis.  Additionally, an exciting new system, 
Fluorescence Molecular Tomography (FMT), was developed to perform 3D NIR imaging.  Similar 
to fluorescent imaging, the Nuance system can be used to perform more detailed ex vivo 
imaging of frozen sections. 
In vivo and ex vivo micro-computed tomography (microCT) 
In recent years, micro-Computed Tomography (microCT) has gained tremendous 
popularity due to its ability to obtain both high resolution 3D images of trabecular and cortical 
bone and yield accurate quantification within specified parameters.  To date, the highest degree 
of accuracy has been achieved using ex vivo scanners such as the Scanco microCT (SCANCO 
Medical) (141, 168-171), which is likely due to diminished tissue deformation and 
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contamination.  However, recent optimization of scanner protocols has enabled the use of in 
vivo microCT to accurately detect changes in bone volume in a single mouse over time (141). 
Since its establishment, microCT technology has been adapted significantly to more 
accurately detect specific models of disease.  As is the case for breast tumor-induced bone 
disease, ex vivo microCT is becoming increasingly popular as a method for detecting murine 
bone volume post-mortem.  Initial reports of microCT in monitoring tumor-induced bone 
disease were conducted in a rat model of breast cancer bone disease and utilized an ex vivo 
microCT similar to those used today (172).  Accordingly, numerous publications since that study 
have utilized microCT as a primary method of reporting changes in bone volume and structure 
as a result of tumor burden (173-176).  
While the utility of ex vivo microCT in detecting bone volume has not been refuted, its 
degree of efficacy has been obviously limited to end-point analyses.  Until recently, the use of in 
vivo microCT to monitor changes in tumor-induced bone disease in a longitudinal study was 
considered unlikely due to concerns of radiation affecting tumor cell growth or the health of the 
animals, and therefore low-resolution Faxitron analyses have been the conventional method for 
monitoring tumor-induced bone disease in vivo.  Indeed, Cowey and colleagues (2007) reported 
that nude mice exposed to microCT radiation exhibited an increase in tumor burden by 
histological analyses, but not by bioluminescent imaging, and that exposure to CT radiation may 
enhance the potential for metastasis to specific skeletal locations (177).  Conversely, Johnson et 
al. reported that modifications to the scanner protocol which optimize resolution with scan time 
and intensity do not yield significant differences in tumor burden in vivo (141).  Furthermore, 
the modified protocol enabled longitudinal analyses of bone volume in individual mice 
throughout the study.  
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Despite the advances in ex vivo and in vivo microCT, the low throughput of these 
systems in both scan time and analysis remains a serious limitation to the technology.  This is in 
part due to the nature of microCT analysis, which is both cumbersome and time-consuming, and 
requires significant training for accurate analyses.  Recently, however, Hojjat et al reported a 
method for automating microCT analyses of the vertebrae and trabeculae in tumor-bearing rats 
with metastatic bone disease using an automated algorithm created from a combination of 
registration and thresholding techniques (178, 179).  These techniques are similar to published 
analyses, but increase throughput by automation. While this automated technique has not been 
extensively tested, it may be a potential avenue for increasing throughput for large-scale 
microCT analyses.  
Micro-positron emission tomography (microPET) 
18Fluorin-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is 
commonly used clinically to measure the size of a tumor and to determine if a tumor is 
responding to therapy.  This technology relies on the greater metabolic activity of the tumor 
cells over normal cells, which causes the cancer cells to uptake the FDG prior to normal cells 
(180).  FDG-PET imaging is not ideal for all tumor types, since some tumors do not preferentially 
uptake FDG-PET (181-183), but PET imaging is highly successful clinically in breast cancer 
patients with bone metastases (184, 185). 
In addition to FDG, many other PET probes are used both clinically and pre-clinically to 
detect changes in cellular proliferation, angiogenesis, hypoxia, and other cellular events (180).  
One of the appeals of PET imaging in pre-clinical models is that often times identical approaches 
are taken clinically, making the translation of findings more applicable (186).  Over the past 
decade, FDG-PET imaging has become more popular for use in animal models of tumor 
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metastasis to bone (187, 188) since it allows for the detection of relatively small tumors, but 
many other PET probes are available and frequently used in other cancer models. 
Because of the nature of the imaging, tumors should be detectable regardless of their 
depth, and tumor cells do not need to be altered in order to visualize them in vivo.  FDG-PET and 
other PET imaging techniques are highly promising for monitoring the growth of tumor in bone 
over time.  However, mainstream use of the technology is likely to be severely limited by the 
expense of the equipment, the requirement of highly skilled individuals to run the equipment 
and analysis, and the length of time required for both the image acquisition and the analysis.  
Despite these issues, PET remains a very promising technique for detecting tumors early. 
In addition to being used to detect tumors, PET imaging using 18F-Fluoride can be 
utilized to image bone directly.  Unlike MDP (discussed in detail in the next section), Fluoride 
binds directly to the bone matrix, but similarly it preferentially binds to areas of high bone 
turnover (186).  However, due to the slower imaging time requirements (compared to 
scintigraphy), PET imaging is not the standard approach clinically. 
More recently, investigators at Vanderbilt University have used PET imaging with TSPO 
(translocator protein), which was previously known as PBR, to detect solid tumors since it is 
expressed at elevated levels in the mitochondria of tumor cells (165, 166, 189, 190).  Our group 
has preliminary data to suggest that PET imaging with TSPO is more sensitive than FDG in 
detecting tumors in bone, and we intend to pursue PET imaging using TSPO to monitor tumor 
cells in bone in the future.  
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Micro-single photon emission computed tomography (microSPECT) 
Clinically, bone scans using 99mTC-MDP (technetium methylene diphosphonate) 
scintigraphy have commonly been used to determine the presence of tumor in bone.  In this 
technique, the uptake of MDP is greatest at sites of high bone turnover (191).  This technology 
detects alterations in normal bone remodeling, which makes it a very successful tool for 
diagnosing tumor bearing areas of bone; however, slow growing tumors and tumors that do not 
alter normal bone remodeling will not be detected.  Furthermore, as with planar radiography, 
certain areas of the skeleton, such as the spine, are difficult to diagnose with this imaging 
modality (191).  Because of this, the clinical use of SPECT (Single Photon Emission Computed 
Technology) technology is more commonly being used to specifically detect tumor cells that are 
affecting bone.  Additionally, recent studies have indicated that combined SPECT/CT imaging 
significantly improves the ability of doctors to diagnose tumors in bone above either technology 
alone (192). 
99mTC-MDP-SPECT has been utilized in a number of animal studies of bone metastases 
(177, 193).  This technique can be very successful in some cases, but the animal imaging 
equipment tends to be less sensitive and lower resolution than the human scanners.  Due to 
this, radiotracers need to be more specific and frequently require greater specific radioactivity 
(186).  However, much like microPET imaging, microSPECT is very time consuming for animal 
models, and its use is therefore usually limited to only a few animals per group.  Also, detecting 
lesions in younger mice can be difficult, since they have high bone turnover in the distal femur 
and proximal tibia, which also corresponds to where tumors seem to metastasize most 
frequently.  
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Magnetic resonance imaging (MRI) 
Magnetic Resonance Imaging (MRI) has been used for decades clinically, especially for 
the diagnosis of brain tumors.  One clinical benefit to this technology over PET and SPECT is that 
it does not rely on ionizing radiation.  It has been highly successful in the diagnosis of tumor and 
other diseases in soft tissue, but until recently it has not been applied readily to the examination 
of bone.  This is primarily due to the fact that MRI relies on visualizing differences in the 
relaxation times of water (194).  While like all tissues bone contains some water, it contains little 
in comparison to soft tissues, making it difficult to gain information from MRI, especially in 
animal models where the resolution needs to be greater.  Despite these limitations, many 
clinical groups are beginning to apply MRI technology to patients with bone metastases with 
great success.  Some studies even suggest that MRI is more sensitive than 18FDG-PET or bone 
scintigraphy for detecting bone metastases in patients (195).  There are many different MRI 
techniques, but perhaps the most applicable to bone are ADC (Apparent Diffusion Coefficient) 
and DCE (Dynamic Contrast Enhanced).  While both of these techniques have been used to 
image soft tissue tumor and the brain in mouse models, imaging mouse skeletal components is 
much more complicated due to the small size of the mouse bones (196-199).  Despite this, we 
and other bone groups are working closely with imaging center personnel to apply MRI 
technology to mouse models of bone metastases.  However, one group has successfully applied 
Diffusion Weighted MRI to monitor the treatment response of prostate tumor bearing mice with 
skeletal metastasis (200).  Other groups have had more success using the nude rat model for MR 
imaging of tumor-bearing bones.  For example, one group used longitudinal DCE MRI to 
measure changes in tumor vasculature with drug treatments (201, 202). 
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Co-registration of multiple imaging modalities 
Since each technology tells only part of the story, the use of multiple modality imaging 
will provide a more comprehensive view of both the bone micro-environment and tumor 
properties. Surprisingly, co-registration of imaging modalities can actually give researchers more 
information than the simple combination of the individual modalities.  In other words, the sum 
of these imaging modalities is greater than their individual parts.  For example, probably one of 
the easiest images to co-register is PET or SPECT with CT, since they can be performed on the 
same instrument. The combination has allowed the detection of lesions that would not have 
otherwise been detectable with either technology alone (203, 204).  However, it is feasible to 
combine images not acquired on the same apparatus.  For example, the Vanderbilt Imaging 
Center has co-registered Matrix-Assisted Laser Desorption/Ionization (MALDI), which is acquired 
using tissue sections, with whole body MRI in a mouse model (205).  Another group has co-
registered MRI, CT, and PET images using patient data, and at the time cautioned against 
improper registration leading to biased information (206).  However, co-registration procedures 
are continuing to improve, and in the future will likely be able to provide abundant information 
both in small animal models and clinically.  
Current promising clinical targets 
Despite decades of research focusing on the treatment of bone metastases, they remain 
incurable.  Bisphosphonates are currently the clinical standard of care for treating patients with 
bone metastases, and have been highly effective in patients to reduce fractures and improve 
quality of life (207).  However, they are not a permanent cure and are not without risk. Severe 
side-effects are rare, but include severe muscle pain, and osteonecrosis of the jaw and atypical 
subtrochanteric fractures in patients with long term high-dose treatments (208-210).  Because 
36 
 
of these risks, newer drugs are currently of great interest.  The emerging drug for clinical use, 
Denosumab or XGEVA™ (Amgen), which targets RANKL has been demonstrated to reduce bone 
turnover and increase bone density in clinical studies (211).  Interestingly, this drug seems to 
have the capability of inhibiting tumor growth, yet this seems likely to be an indirect effect 
(212).  However, XGEVA™ also presents safety risks, including hypocalcemia and osteonecrosis 
of the jaw, though the prevalence is unclear due to limited clinical data (208).  Despite the 
clinical success of these drugs, they do not target the tumor, and therefore do not address the 
root of the disease and are not a cure for tumors growing in the bone.  Therefore, other groups 
are investigating drugs that can target the tumor cells. 
Tgf-β inhibition 
One such approach is by inhibiting Tgf-β.  Tgf-β is thought to affect both the tumor cells 
and the micro-environment, suggesting that an inhibitor of this pathway may be able to block 
bone destruction through multiple targets.  Thus far, Tgf-β inhibitors have been very successful 
with several groups demonstrating that they can inhibit metastasis to soft tissues (213, 214) and 
bone (215). In addition to direct effects on the tumor, they appear to have positive effects on 
bone in non-tumor bearing mice.  It has been reported by two independent groups that Tgf-β 
inhibitors 1D11 (Genzyme, Cambridge, MA) and SD-208 (Scios, Inc., Sunnyvale, CA) increase 
bone density and biomechanical properties as well as numerous measures of bone quality (e.g., 
trabecular bone architecture and mineral:collagen ratio) (12, 13). These studies also 
demonstrate an increase in osteoblast number and a decrease in osteoclast number in the bone 
marrow of healthy mice.  Taken together, these data suggest that Tgf-β inhibition may be an 
ideal drug for bone metastases, since it can both inhibit tumor growth and improve bone 
quality.  Despite their promise in pre-clinical models, their use may be complicated in patients 
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due to the biphasic effects of Tgf-β in tumor growth and its effects throughout the body on 
normal cells (216), with particular concerns in patients with residual primary tumor or multiple 
metastases.   
Tumor growth inhibition 
It is clear that more specific drugs are needed to target tumors growing in bone.  Some 
potential pathways are being studied by multiple groups to block metastasis and establishment 
in bone through inhibition of integrins (217), SDF-1/CXCR4 (218), and ROCK (97, 219).  Other 
groups have specifically targeted certain cell types, such as inhibiting osteoclasts using Src 
inhibitors (220, 221) and stimulating osteoblasts using Dkk1 inhibitors, while still others are 
investigating inhibitors of the tumors themselves.  Some current promising approaches include 
the histone deacetylase inhibitor vorinostat, which inhibits tumor growth in bone, but can 
stimulate bone loss (222), suggesting possible combination treatments to protect bone.  
Erlotinib, an inhibitor against EGFR tyrosine kinase, has been successfully tested in a preclinical 
model of non-small-cell lung cancer metastasis to bone, and effectively inhibited release of 
osteolytic factors such as PTHrP and IL-8 (223).  In our studies and others’, inhibiting the 
transcription factor GLI2 appears promising in melanoma (152) and breast cancer metastasis 
(36, 61).  Inhibitors to this pathway are currently under investigation in pre-clinical models of 
prostate cancer and are promising for treatment of primary tumor burden (62).  For bone they 
are an attractive target since Gli2 has limited expression in adult tissues, suggesting minimal 
side-effects. 
Guanosine nucleotides 
Other inhibitors aimed at blocking tumor release of osteolytic factors include guanosine 
metabolites, which have been clinically utilized with varying degrees of success for many years 
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in cancer patients, primarily as the second or third line of treatment for acute leukemia.  These 
purine analogs compete with endogenous purines for incorporation into DNA and disrupt DNA 
replication and subsequent cellular proliferation (224), which has a modest antitumor effect.  6-
Thioguanine (6-TG) was initially identified during a cell-based screen for low-molecular weight 
compounds that inhibit PTHrP promoter activation, and has been reported to elicit specific 
inhibitory effects on PTHrP expression at low doses and with little cytotoxicity (27).  This same 
publication also reported that 6-TG inhibits PTHrP activity in human breast cancer cells in vitro 
and inhibits tumor burden and tumor-induced bone destruction in vivo in a murine model of 
breast cancer metastasis to bone (27), and we have published that the inhibitory effects of 6-TG 
on PTHrP are mediated through GLI2 transcription regulation (Johnson et al., in press).   
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CHAPTER II 
MATERIALS AND METHODS 
Molecular biology 
Maintenance of cell lines 
The human osteolytic breast cancer cell line MDA-MB-231 was obtained from ATCC 
(American Type Tissue Culture Collection, Manassas, VA, USA) and a bone metastatic variant 
generated in our lab was used for all in vitro and in vivo experiments, as previously published 
(28, 36).  The human osteolytic squamous non-small cell lung carcinoma cell line RWGT2 was 
generated by the Mundy Laboratory (San Antonio, TX, USA), as previously published (149).  
MDA-MB-231 cells, RWGT2 cells, and human metastatic prostate cancer cell line PC-3 (ATCC), 
were maintained in DMEM (Cell-gro, Manassas, VA, USA) plus 10% Fetal Bovine Serum (FBS; 
Hyclone Laboratories, Logan, UT, USA) and 1% penicillin/streptomycin (P/S; Mediatech, 
Manassas, VA, USA).  The murine chondrocyte cell line TMC23 and human non-osteolytic breast 
cancer cell line MCF-7 were obtained from ATCC and cultured in α-MEM (Invitrogen, Carlsbad, 
CA, USA) plus 10% FBS and 1% P/S.  All cell lines are routinely tested for changes in cell growth 
and gene expression.   
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
RNA was extracted from cells using RNeasy Mini Kit (QIAgen), per manufacturer’s 
instructions. cDNA was synthesized using SuperScript III First-Strand Synthesis System for RT-
PCR (Invitrogen) and random hexamers from 1-5µg of total RNA per manufacturer’s instructions. 
cDNA (1.0µl) was used for RT-PCR using Platinum PCR SuperMix (Invitrogen).  RT-PCR was 
conducted for the human homologues of the Hedgehog signaling receptors Patched (PTCH) and 
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Smoothened (SMO).  Primers for amplifying hPTCH are as follows: F, 5’-
CGCCTATGCCTGTCTAACCATGC-3’; R, 5’-TAAATCCATGCTGAGAATTGCA-3’.  PCR was performed 
on the Bio-Rad iCycler with the following cycling conditions:  94°C for 2min, (94°C for 30sec, 
66°C for 1min, 72°C for 30sec) x35 cycles, 72° for 2min.   Primers for hSMO amplification are as 
follows: F, 5’-TTACCTTCAGCTGCCACTTCTACG-3’; R, 5’-GCCTTGGCAATCATCTTGCTCTTC-3’.  PCR 
was performed with the following cycling conditions: 94°C for 4min, (94°C for 30sec, 56°C for 
1min, 72°C for 45sec) x35 cycles, 72° for 2min.   
Quantitative real-time RT-PCR (Q-PCR) 
PTHrP, GLI2, and 18s mRNA expression were measured by Quantitative Real-Time RT-
PCR (Q-PCR).  After 48 hours’ incubation, RNA was extracted from cells using RNeasy Mini Kit 
(QIAgen, Valencia, CA, USA), per manufacturer’s instructions.  Complementary DNA (cDNA) was 
synthesized from 1-5 μg of total RNA using SuperScript III First-Strand Synthesis System for RT-
PCR (Invitrogen) and random hexamers, per manufacturer’s instructions.  cDNA was serially 
diluted to create a standard curve, and for TMC23 samples, was combined with SYBR Green PCR 
Master Mix (Applied Biosystems) and GLI2, PTHrP, or GAPDH primers, as previously published 
(225).  A dissociation curve was created and a single peak was confirmed for each primer.  MDA-
MB-231 and RWGT2 cDNA was combined with TaqMan Universal PCR Master Mix (Applied 
Biosystems), and primer: TaqMan PTHLH (Hs00174969_m1), TaqMan GLI2 (Hs00257977_m1), or 
TaqMan Euk 18S rRNA (4352930-0910024; Applied Biosystems).  Samples were loaded onto an 
optically clear 96-well plate (Applied Biosystems) and the Q-PCR reaction was performed under 
the following cycling conditions:  50oC for 2min, 95oC for 10min, (95oC for 15sec, 60oC for 1min) 
x40 cycles on the 7300 Real-Time PCR System (Applied Biosystems).  Q-PCR reactions were 
quantified using the 7300 Real-Time PCR Systems software (Applied Biosystems). 
41 
 
Cell proliferation assay 
In vitro cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay using the CellTiter 96 
Aqueous  Non-Radioactive Cell Proliferation Assay Kit (Promega).  Briefly, 2,000 cells/well were 
plated in 96-well plates in quadruplicate, and growth was measured at days indicated 
spectrophotometrically at 450nm on a Synergy2 plate reader, per manufacturer’s instructions. 
Western blot 
Cells were harvested for protein into a 1X radio-immunoprecipitation assay (RIPA) lysis 
buffer (ThermoScientific) supplemented with a cocktail of protease inhibitors (Roche, Basel, 
Switzerland).  Equal protein concentrations were prepared for loading with Laemmli sample 
buffer and electrophoresis was performed on sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) Mini-Protein II ready gels (Bio-Rad, Hercules, CA, USA).  Separated 
proteins were then transferred to Polyvinylidene fluoride (PVDF) in transfer buffer [25 mmol/L 
Tris, 192 mmol/L glycine, 20% (v/v) methanol (pH 8.3)] at 200mA at room temperature for 90 
minutes.  Membranes were blocked with either 1X TBS buffer containing 1% Tween 20 (1XTBST) 
for 1 hour at room temperature and incubated with a 1:200 dilution of Omni-probe α-His 
antibody (Santa Cruz Biotechnology) in blocking buffer, or blocked with 1X TBS containing 1% 
BSA and 1% milk for 1 hour at room temperature and incubated with a 1:200 dilution of Gli2 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in blocking buffer for 1 hour at room 
temperature.  The membrane was washed with 1XTBST and signal was detected using an 
enhanced chemiluminescence system (Amersham, Piscataway, NJ, USA).  Membrane was 
stripped using Restore Western Blot Stripping Buffer (Thermo Scientific), washed with 1XTBST, 
and re-probed with a 1:5000 dilution of β-actin antibody (Sigma-Aldrich) as a loading control.       
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Transfections 
The CMV-GLI2-GFP construct was kindly provided by Dr. Rune Toftgard (226) (Karolinska 
Institute, Huddinge, Sweden).   The GLI2 WT, mTCF, and mSmad promoter constructs were 
kindly provided by Dr. Sylvianne Dennler (60) (INSERM, Paris-Diderot University, Paris, France).  
The Gli2-Rep construct was kindly provided by Dr. Ilona Skerjanc (227) (University of Western 
Ontario).  Cells were plated at a density of 5.0×104 per well in a 24-well plate (pGL3, GLI2 WT, 
mTCF, mSmad, and PTHrP promoter constructs) or 1.8×106 in a T25 flask (CMV-GLI2-GFP, GLI2-
His, GFP, and pcDNA) 16-24 hours prior to transfection. Cells were transfected with 5 μg of 
construct.  All transfections were performed using LipofectAMINE Plus (Invitrogen, Carlsbad, CA, 
USA) reagent per the manufacturer’s instruction.  MDA-CMV-GLI2-GFP, MDA-GFP, MDA-pcDNA, 
and MDA-Gli2-Rep stable cell lines were selected for antibiotic resistance into single cell clones 
by limiting dilutions or pooled colonies under 400µg/ml getecin (G418) selection medium 48 
hours post-transfection and maintained in culture medium supplemented with 200µg/ml G418.  
For promoter studies, cells were harvested for luciferase assay 24 hours post-transfection, per 
manufacturer’s instructions (see promoter luciferase assay). 
mRNA stability 
Confluent cells were treated with either 6-TG or purine as a control (see cell treatment, 
6-TG), and actinomycin D [0.8 micromolar (μM)], a transcription inhibitor, was added 2 h after 6-
TG treatment. Total RNA was extracted 24 hours after treatment and mRNA quantitative 
analyses were performed by Q-PCR as described above.  
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Promoter luciferase assay 
Following successful transfection, cells were rinsed once with 1×PBS and directly lysed 
with 100 μl 1×Passive Lysis Buffer (Promega, Madison, WI, USA).  Cells were subjected to at least 
one freeze-thaw cycle to complete lysis.  Relative luminescence of cell lysate was determined 
using Luciferase Assay Reagent II (Promega) and Stop and Glo Buffer (Promega), per 
manufacturer’s instructions, and performed on a Synergy 2 plate reader and luminometer 
(BioTek, Winooski, VT, USA).   
Cell treatments 
Cyclopamine.  Cyclopamine (LC Labs) was re-constituted in (2-Hydroxypropyl)-beta-
cyclodextrin solution 45% (w/v) in HOH (Sigma-Aldrich).  For in vitro studies, 1-10µmol (with 
data from 3µmol shown) cyclopamine or tomatadine was added to cell culture medium and cells 
were harvested 24 hours later.   
Tgf-β.  Recombinant Tgf-β (R&D Systems, Inc, Minneapolis, MN, USA) was re-constituted 
in 4mM HCl and 1mg/ml bovine serum albumin (BSA).  Prior to treatment, cells were washed 
once with serum-free medium, and Tgf-β added at 5-10ng/ml to serum-free cell culture 
medium.   
2G7. Tgf-β neutralizing antibody 2G7 was obtained from the Vanderbilt Monoclonal 
Antibody Core.  Prior to treatment, cells were washed once with serum-free medium, and 2G7 
or control IgG 12CA5 was added at 50μg/ml to serum-free DMEM. 
LiCl.   Lithium Chloride solution (LiCl, 8M solution; Sigma-Aldrich) was added at 20mM 
(228, 229) or 40mM (228) to serum-free DMEM, as specified in text.   
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XAV939 and VU-WS113.  Received 10mmol stock of XAV939 (Novartis, Basel, 
Switzerland) and VU-WS113 kindly provided by Dr. Ethan Lee and added drug or DMSO control 
at 100nmol, 1μmol, or 10μmol to DMEM supplemented with 5ng/ml recombinant Tgf-β to spike 
Gli2 levels prior to inhibition.  MDA-MB-231 cells were also treated in serum-free conditions 
with similar results.   
GANT58/GANT61.  GANT58 and GANT61 were obtained from the NCI (Bethesda, MD, 
USA).  GANT58 and GANT61 were re-suspended in methanol for in vitro studies and added at 
10μmol to serum-free DMEM, unless otherwise specified in text. 
6-TG.  Cells were plated at a density of 5.0×104 per well in a 24-well plate, 7.2×105 per 
well in a 6-well plate, or 1.24×106 per well in a T25 flask 16-24 hours prior to treatment.  Cells 
were washed once with serum-free DMEM, and 6-TG (Sigma-Aldrich, St. Louis, MO, USA) was 
added to cells at 100 μmol-1 mmol in DMEM supplemented with 10% FBS and 1% P/S and 
incubated for 2, 4, 8, or 24 hours.   
PCR array 
MDA-MB-231 cells were seeded onto soft Polyacrylamide (PA) gels or tissue culture 
polysterene (TCPS) coated in Fibronectin (Fbn) at 1.92 x 106 cells/well and harvested for RNA as 
described above after 24 hours incubation.  cDNA was synthesized from 1μg RNA per 
manufacturer’s instructions for the RT2Profiler PCR Array System for Wnt Signaling 
(SABiosciences, Frederick, MD, USA).  Samples were loaded onto pre-coated 96-well array plates 
and reverse transcription was performed on the 7300 Real-Time PCR System (Applied 
Biosystems) per manufacturer’s instructions as follows:  95oC for 10min, (95oC for 15sec, 60oC 
for 1min) x 40, (95oC for 15sec, 60oC for 1min, 95oC for 15sec) Dissociation step.  Reactions were 
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quantified using 7300 Real-Time PCR Systems software for CT value, per manufacturer’s 
instructions. 
β-catenin nuclear/cytoplasmic fractionation 
MDA-MB-231 cells were seeded onto soft Polyacrylamide (PA) gels, tissue culture 
polysterene (TCPS), or tissue culture polysterene coated in Fibronectin (TCPS+Fbn) at 1.92 x 106 
cells/well and harvested for cell pellets after 24 hours incubation.  Pellets were washed twice 
with 1XPBS and fractionated into cytoplasmic and nuclear fractions using the NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Pierce/Thermo Scientific, Rockford, IL, USA), per 
manufacturer’s instructions.  Briefly, cellular membranes were disrupted using lytic buffer to 
expose cytoplasmic proteins, which were immediately harvested and stored at -80oC.  
Remaining nucleus was recovered and lysed to yield nuclear fraction, which was immediately 
harvested and stored at -80oC.  According to the manufacturer, less than 10% contamination 
between cytoplasmic and nuclear fractions is anticipated (Pierce/Thermo Scientific).   
β-catenin/Dkk1 shRNA 
MDA-MB-231 cells were plated at a density of 1.92 x 106 cells/well and transfected with 
shRNA against CTNNB1 (β-catenin) or DKK1 (Open Biosystems/Thermo Scientific, Huntsville, AL, 
USA) 24 hours after plating.  For transfection, 1.15μg of construct was diluted in 115μl Optim-
MEM (CellGro), and 2.5μg Lipofectamine2000 was diluted in 115μl Opti-MEM.  The 
Lipofectamine mixture was added to the construct, and incubated for 20 minutes at room 
temperature.  Cells were washed once with Opti-MEM and left in 800μl Opti-MEM/well.  
Following incubation, construct and Lipofectamine solution was added to each well and 
incubated for 6 hours.  Following incubation, 2mL of DMEM supplemented with 20% FBS was 
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added to each well.  Tgf-β treatment was started 24 hours following transfection, and cells were 
harvested for RNA 24 hours later, as described above. 
Stiffness studies 
Tissue culture polystyrene (TCPS) and polyacrylamide (PA) hydrogels were employed to 
examine the effects of substrate rigidity on Wnt signaling in 2D in vitro culture.  To facilitate cell 
adhesion and ensure that the surface chemistry was constant for all substrates tested, 
Fibronectin (Fbn) was adsorbed to the surface of the substrates by incubating them in a 4µg/ml 
solution of Fbn in PBS at 4°C overnight.  PA hydrogels were synthesized by copolymerizing a 10% 
solution of acrylamide and bis-acrylamide in water via free-radical polymerization using a redox 
pair of initiators [tetramethyl ethylene diamine (TEMED) and 10% ammonium persulphate (APS) 
in water]. Additionally, acrylic acid N-hydrosuccinimide (NHS) ester was copolymerized to the 
surface of the gels.  The NHS-acrylate layer was then allowed to react with a solution of Fbn in 
HEPES. To measure the surface concentration of Fbn, coated substrates were incubated in a 
solution of Fbn antibody (1:1000) followed by incubation with a secondary HRP-conjugated 
antibody.  The relative amount of adsorbed antibody was then quantified by reaction with 2'-
azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) and subsequent optical density reading 
at 405nm.  All PUR and PAA substrates were prepared at the same surface concentration of Fbn 
that yielded an optical density of 0.12 absorbance units cm-2.  
Animal studies 
Animals 
All animal protocols were approved by Vanderbilt University Institutional Animal Care 
and Use Committee and were conducted according to NIH guidelines.  Female, 4-week old 
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athymic nude mice (at sacrifice, n=8, vehicle; n=13, cyclopamine and n=10, empty vector; n=7, 
Gli2-Rep and n=13, PEG; n=11 GANT58) were anesthetized by continuous isoflurane and 
inoculated with 100,000 MDA-MB-231-GFP, MDA-MB-231-cntrl, or MDA-MB-231-Gli2-Rep cells 
re-suspended in PBS via intracardiac injection into the left cardiac ventricle using a 27-gauge 
needle, as previously described (27, 36, 69).  Mice were imaged weekly and sacrificed 4 weeks 
post-tumor cell inoculation.  For mammary fat pad injections, female 4-week old athymic nude 
mice (at sacrifice, n=8/group for Gli2-Rep studies and n=8, PEG; n=6 GANT58) were anesthetized 
by continuous isoflurane and an incision was made on the ventral lower abdomen.  The left 
inguinal mammary gland was inoculated with 1,000,000 MDA-231-Gli2-Rep or MDA-231-cntrl 
cells (for Gli2-Rep studies) or MDA-MB-231-GFP cells (for GANT58 studies) re-suspended in PBS.   
Tumor size was assessed by caliper measurements twice per week.  Mice were sacrificed three 
weeks after tumor cell inoculation, and tumors excised, measured, and weighed.  For 
cyclopamine studies, beginning two weeks post-tumor cell inoculation, mice were treated daily 
with either 10mg/kg cyclopamine or control tomatadine analog by i.p. injection, as previously 
published (230).  For GANT58 studies, GANT58 powder was re-suspended in 25% polyethylene 
glycol (PEG)/75% sterile PBS, and mice were treated at 25mg/kg/day with either GANT58 or 
PEG/PBS vehicle by i.p.injection in tumor-bearing and normal mice.  For non-tumor studies n=5, 
PEG; n=4, GANT58.  For intratibial tumor-bearing studies, 4-week old athymice nude mice were 
inoculated with 2×105 MDA-MB-231-GFP cells directly into the tibia and treated at 25mg/kg/day 
with PEG (n=5) or GANT58 (n=7) by i.p. injection.  Mice were sacrificed after 4 weeks after tumor 
cell inoculation. 
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Histology/histomorphometry 
Hind-limb specimens (tibiae and femora) were removed during autopsy and fixed in 10% 
neutral buffered formalin (Fisher Scientific) for 48 hours at room temperature.  Bone specimens 
were decalcified in 10% EDTA for 2 weeks at 4oC and embedded in paraffin.  5µm-thick sections 
of bone were stained with hematoxylin & eosin (H+E), orange G, and phloxine.  Tumor burden in 
the femora and tibiae was examined under a microscope and quantified using Metamorph 
software (Molecular Devices, Inc.) and region of interest (ROI) analysis.  
Conventional imaging modalities 
Radiographic imaging 
Mice were radiographically imaged weekly beginning one week post-tumor cell 
inoculation using a Faxitron LX-60.  Specifically, mice were anesthetized deeply with 
ketamine/xylazine and laid in a prone position on the imaging platform.  Images were acquired 
at 35 kVp for 8 seconds.  Lesion area and number were measured using quantitative image 
analysis software (Metamorph, Molecular Devices, Inc.) by ROI analysis.  All data are 
represented as mean lesion area and number per mouse. 
Ex vivo microCT 
Tibiae were analyzed using the Scanco microCT 40.  Specifically, 100 slices from the 
proximal tibiae were scanned at 12 μm resolution.  Images were analyzed using the Scanco 
Medical Imaging software to determine the bone volume/total volume (BV/TV), trabecular 
number, spacing and thickness, and connectivity density. 
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Fluorescent imaging 
GFP tagged tumor cell growth was measured and quantified using the CRi MAESTRO 
system.  Mice were anesthetized using isoflurane and then placed in the MAESTRO imaging 
equipment. After the image was obtained, it was spectrally unmixed to remove the background 
fluorescence.  Images were quantified using ROI software that is supplied with the MAESTRO 
system. 
Evaluation of live animal microCT for quantitative analysis of tumor-induced osteolysis 
Single-group longitudinal study 
Preliminary studies were first performed on 16 mice to determine the effect of weekly 
irradiation on this cell line. Mice were broken down into four groups, and two different µCT 
protocols were performed using the Imtek MicroCAT II, one high resolution (Bin-2), and one 
lower resolution (Bin-4), with imaging being performed 1 (n=4), 2 (n=6), or 3 time(s) (n=3 Bin-2, 
n=3 Bin-4) during the four week study, with the group scanned one time receiving the CT scan 
only at sacrifice.  The Bin-2 protocol used 80 kVp, 500 µA with 900 msec per projection and 600 
projections over 360° for a total scan time of approximately 20 minutes, while the Bin-4 
protocol was acquired with 80kVp, 500µA with 600msec per projection and 300 projections over 
360° for a total scan time of approximately 10 minutes.  All images were reconstructed to 512 × 
512 × 512 voxels, with Bin-2 having 0.1 × 0.1 × 0.05 mm3 voxel size and Bin-4 having 0.159 × 
0.159 × 0.062 mm3 voxel size.  The radiation dose from Bin-2 and Bin-4 were estimated to be 
148.3 mGy and 49.4 mGy respectively.  Both protocols were reconstructed with the same 
conebeam filtered back projection algorithm with a Hamming filter.   
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Two-group longitudinal study 
MDA-MB-231 tibia-injected mice were imaged using the Imtek MicroCAT II weekly for 
four weeks. Sixteen mice were divided into two groups, one treatment group (n=8) and one 
control group (n=8).  All mice were injected in one tibia with tumor cells at week 0, and the 
treatment group received one tail-vein injection of 0.1mg/mouse of the bisphosphonate 
zoledronic acid on day 6 after injection.  Images were acquired at weeks 1, 2, 3, and 4 post 
injection for all 16 mice, using the same Bin-2 protocol as was performed in the preliminary 
study, and were reconstructed to have 512 × 512 × 512 voxels, each 0.15 × 0.15 × 0.212 mm3 in 
size. 
Longitudinal CT quantification procedure 
Image quantification of bone volume was performed using a threshold method based on 
Hounsfield Units (HU).  Due to unstable detector performance and differences between 
intensity scales in each image, all images being quantified were first converted to Hounsfield 
Units (HU) to give them all the same intensity scale and to allow for reasonable week to week 
comparisons.  In each image, the average value of ROIs drawn in air, bed (plastic), and bone 
were fitted to -1000, 0 and 1700 respectively; the resulting linear fit was used to convert all 
voxel values to HU.  All image analysis was done using Amira 5.2 (Visage Imaging, Inc).  
Following conversion to HU, each image was roughly cropped into two parts: the tibia 
region of the lesion limb, and the contra-lateral tibia region for use as a control limb.  The lesion 
limb or control limb images were registered to the first time point using Amira’s Affine 
Registration function using the Correlation metric with a Quasi Newton optimizer step. Each 
limb was then carefully cropped to extend from just below the patella, but above the growth 
plate, to the point where the tibia and fibula join, with the fibula being removed as well.  It was 
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determined that a threshold of 1000 HU was most sensitive to changes in bone volume and 
subsequently applied to each image.  The number of voxels that were above the threshold were 
then summed and converted to a volume measure of the tibia. 
Tumor cell intratibial inoculation and histological processing 
Confluent MDA-MB-231 human breast cancer cells were trypsinized, washed and re-
suspended in PBS for injection into the right tibia of anesthetized 4-week-old female athymic 
nude mice (Harlan Sprague Dawley, Inc.) at 2.5 x 105 cells per mouse. Contralateral intratibial 
injections of PBS were used as an internal control for each mouse.  Animals were sacrificed four 
weeks after injection. Hind limb specimens (tibia and femora) were removed during autopsy and 
fixed in 10% neutral buffered formalin (Fisher Scientific) for 48 hours at room temperature. 
Bone specimens were decalcified in 10% EDTA for 2 weeks and embedded in paraffin. Bone 
sections were stained with H+E, orange G and phloxine.  Histomorphometry was used to analyze 
tumor burden in the tibiae and femora using Metamorph software (Molecular Devices, Inc.).    
Specifically, using the drawing tool in Metamorph the region between the cortices directly 
below the growth plate was selected and calculated by the software as the total area in 
centimeters2.  The tumor, as determined by H+E staining, was selected using the same 
approach.  Tumor burden was calculated as a percentage of tumor area over total tissue area.  
Multiple levels of bone sections were stained and imaged, and all statistical analyses were 
quantified at the same histomorphometric level.  All statistical analyses were performed using 
InStat version 3.03 software (GraphPad Software Inc.). 
Statistical analyses for longitudinal studies 
For statistical analysis of the two-group longitudinal microCT data, we fitted a linear 
mixed model to the data and included random subject effect to account for the correlation of 
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the longitudinal measurements from the same subject.  Slope analysis for each group was 
performed and compared to zero.  To adjust for multiple comparisons, we used 0.05/8=0.006 as 
the cut off point for p-values being statistically significant.  The slope of the tibia volume as a 
function of time in the untreated control limb group was found to be significantly less than zero 
(p<0.0001) while the slope of the treated control limb was found to be significantly greater 
(p<0.0001). The statistical differences between the slopes of groups were determined. The 
treated and untreated lesion limb slopes were significantly different (p<0.0001), along with the 
untreated lesion limb and untreated control limb (p<0.0001). There was no statistical difference 
between the treated and untreated control limb slopes (p=0.0132) or between the treated 
lesion limb and treated control limb slopes (p=0.0443). Also for the untreated group, it was 
determined that week 3 and week 4 volumes had significant mean differences between the 
lesion and control limbs with p=0.0031 and p<0.0001 respectively. 
Statistical analyses 
All assays were performed in triplicate, and results were verified in subsequent 
experiments.  All statistical analyses were performed using InStat version 3.03 software 
(GraphPad Software, Inc., La Jolla, CA, USA).  Values are presented as mean ± standard error of 
the mean (SEM), and p-values determined using unpaired t-test, where *p< 0.05, **p< 0.01, 
***p<0.001 unless otherwise stated. 
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CHAPTER III 
RESULTS AND CONCLUSIONS 
Live animal microCT allows for quantitative analysis of tumor-induced osteolysis 
Introduction 
Nearly 70% of breast cancer and 90% of prostate cancer patients with metastatic 
disease will develop bone metastases (231).  In order to investigate breast and prostate tumor 
effects on bone, several small animal models have been developed that are capable of 
producing pathogenesis strikingly similar to the clinical condition in both tumor burden and 
bone disease (27, 69, 232-234).  While these animal models accurately reflect the bone disease 
portion of the clinical disease, small animal imaging has lagged significantly behind clinical 
imaging.  This has hindered pre-clinical rodent models in which drug treatments typically 
commence upon visual evidence of bone disease and is particularly limiting due to the difficulty 
of detecting tumors in animal bone as early as can be detected in human patients.  In addition, 
the lack of precise small animal imaging has limited quantitative longitudinal analyses of animals 
in drug treatment studies.  Therefore, significant improvements to small animal imaging 
modalities are needed. 
Over the past 20 years the primary methods for monitoring cancer bone disease in small 
animal models have relied heavily upon radiography using Faxitron analyses (235).  While this 
approach has been very successful, in our experience it is difficult to accurately view the entire 
skeleton and small, early stage lesions are undetectable by radiography.  In recent years 
microCT analyses have gained popularity due to the ability to obtain high resolution 3-
dimensional images and the degree of accuracy exhibited by this imaging modality.  While the 
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highest resolution images can be obtained by ex vivo scanners, such as the Scanco microCT, the 
utility of these scanners is obviously limited to endpoint analyses.  Recent reports combine 
microCT evaluation with other imaging techniques such as magnetic resonance imaging (MRI) 
and fluorescence stereomicroscopy to generate a more complete evaluation of the bone micro-
environment in metastatic cancer (236), but the limitation of end-point analyses persists.  Our 
group has previously used live animal microCT successfully for imaging bone, but found that 
high resolution scans killed the tumor cells (unpublished data), limiting its utility to endpoint 
analyses.  In addition, it has been reported that certain doses of CT radiation may enhance 
metastasis to specific sites in bone (177).   
Missbach-Guetner et al. addressed several of these issues utilizing a 3-dimensional flat-
panel detector-based Volume Computed Tomography (fpVCT); however, the detector in use is 
fairly uncommon, and the majority of quantification performed was primarily 2-dimensional 
measurements. Quantitative analysis of 3-dimensional bone volume was only reported in one 
mouse, lacking statistical significance, and the method used for quantification was unclear (237).   
In this study, we set out to determine if live animal microCT can be utilized to perform 
reproducible and quantitative longitudinal analyses of bone volume in tumor bearing mice, 
particularly in a drug treatment model of breast cancer metastasis to bone.  To do this we 
utilized the MDA-MB-231 osteolytic breast cancer model in which the tumor cells are inoculated 
directly into the tibia of athymic nude mice and imaged mice weekly by Faxitron (radiography), 
Imtek microT (in vivo), and Maestro (GFP-imaging).  Scanco microCT (ex vivo) and histology were 
performed at end-point for validation.  After establishing a high resolution scanning protocol for 
the Imtek microCT, we determined whether clear, measurable differences in bone volume were 
detectable in mice undergoing bisphosphonate drug treatment.  Bisphosphonates are clinically 
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utilized in breast and prostate cancer metastasis to bone in order to palliate tumor-associated 
bone pain and prevent the recurrence of skeletal related events by binding to the surface of 
bone and inducing osteoclast apoptosis (238).  We found that in vivo microCT can be used to 
obtain quantifiable and longitudinal images of the progression of bone destruction over time 
without altering tumor cell growth.  Additionally, we found that we could detect lesions as early 
as week one after tumor inoculation and that this approach could be used to monitor the effect 
of drug treatment on bone.   
Longitudinal microCT does not alter tumor growth 
In order to determine if microCT protocols could be developed that would allow for 
longitudinal microCT analyses of bone, we inoculated athymic nude mice with the osteolytic 
breast cancer cell line MDA-MB-231.  We chose to use an intratibial model for this study, since 
there is less variability in this model than the intracardiac model, which allowed us to more 
easily validate the technology.    After tumor cell inoculation we utilized two different imaging 
protocols, both with similar radiation doses to those previously reported (177, 237), but at 
different resolutions.  Animals were either imaged three times (weeks 2, 3 and at sacrifice), 
twice (week 3 and at sacrifice), or once (only at sacrifice).  We found by fluorescence imaging of 
the GFP tumor cells (Maestro) that while there was a slight reduction in the relative fluorescent 
units (RFU) at 4 weeks there were no significant changes in the overall RFUs between the groups 
(Figure 3A&B), suggesting no effect on the tumor cell growth over the course of the experiment.  
Although dead cells may still express GFP, we reasoned that the size of the tumors indicated 
considerable tumor growth over 4 weeks.  These observations were verified by histology, which 
also showed no changes in tumor volume after 4 weeks (Figure 3C&D). 
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Figure 3.  Longitudinal microCT does not affect tumor burden in vivo.  Athymic nude mice were 
inoculated with MDA-MB-231 cells and imaged by microCT utilizing a Bin-2 (high resolution) or 
Bin-4 (low resolution) protocol. (A) Mice were monitored for tumor burden by tumor cell 
fluorescence utilizing CRi Maestro. Mice scanned at three time points by microCT at high (far 
left, n = 3) or low resolutions (middle left, n = 3) exhibited no change in tumor burden when 
compared to mice scanned twice (n = 6) or once (n = 4) by microCT at sacrifice. (B) 
Quantification of tumor burden by relative fluorescent units in mice scanned by microCT. (C and 
D) Histomorphometric analysis demonstrated no change in tumor volume in mice scanned at 
multiple time points by microCT when compared to mice scanned only upon sacrifice. Black bars 
represent a length of 500 μm. Columns indicate average group values, and error bars represent 
standard error (SE). Statistics demonstrated nonsignificance across all groups and are therefore 
not visually represented. Statistical significance is considered p < 0.05. 
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Longitudinal microCT illustrates bone loss over time  
Weekly microCTs acquired during the course of the experiment were registered and 
over-laid into a single image so that we could visually see the loss in bone over time in tumor- 
bearing mice versus controls (Figure 4A&E).  Individual scans were rendered at each week and 
can be visualized in Figure 4B-D and F-H.  The representative image illustrates the loss in bone 
during the 3 weeks of image analysis, clearly showing a gradual loss of bone over time.  
Importantly, we were able to generate high resolution images and data such as these for each 
mouse.  In addition, we quantified the changes in percent of bone volume/tissue volume 
(BV/TV) histologically in order to verify the observations found by our microCT data (Figure 4I).   
By histology, we found that although there were no significant differences between the tumor 
leg and control leg, there was a trend toward higher bone volume in the control limb.  These 
data illustrate that longitudinal microCT may be a valid option for imaging tumor-induced bone 
disease over time, which we previously thought was not possible in animal models.  We 
therefore pursued further studies to determine if this modality would be useful in a drug 
treatment model. 
In vivo microCT renders quantifiable longitudinal images of tumor-induced bone destruction 
The most useful application for this imaging tool is in drug treatment models in which 
investigators need to detect lesions at early stages to determine the best time-points for drug 
treatment.  Therefore, we wanted to find methods to quantify the in vivo microCT data similar 
to quantification used in the ex vivo microCT system and histology.  In order to do this we 
treated mice with zoledronic acid one week after tumor cell inoculation, when small osteolytic 
lesions were visible.  We chose this model since it is well-established to reduce bone destruction  
  
 Figure 4.  Longitudinal in vivo
(A) Overlay of registered isosurface volume images from three individual time points of 
longitudinal in vivo microCT scans of control hind limb. (B
renderings of weeks 2, 3, and 4 (sacrifice) of the control hind limb of the same mouse using 
high-resolution microCT. (E) Overlay of registered isosurface volume images from three 
individual time points of longitudinal in vivo microCT scans of tumor
Weekly isosurface volume renderings of weeks 2, 3, and 4 (sacrifice) of the tumor
limb of the same mouse using high
1000 HU. (I) Histomorphometric analyses indica
volume/tissue volume, regardless of the number of microCT scans. Columns indicate average 
group values, and error bars represent standard error (SE). Statistics demonstrated 
nonsignificance across all groups 
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 microCT demonstrates bone loss over time in individual mice.
–D) Weekly isosurface vo
-bearing hind limb. (F
-resolution microCT. All rendering thresholds were set to 
te no significant difference in percent of bone 
and are therefore not visually represented. 
 
  
lume 
–H) 
-bearing hind 
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in animal models and human patients (238), and would therefore provide clear differences in 
bone volume for quantification. 
Initially, we examined the non-treated groups in this study and compared the control 
versus the tumor leg.  Similar to the previous study we cropped and then registered the weekly 
acquired images (Figure 5A&B).  We drew ROIs covering regions of empty space, bed (plastic) 
and bone and generated a calibration curve, which was used to convert each image’s intensity 
values to HU.  Using this approach we found that we could accurately measure the volume of 
bone destruction over time.  These results are displayed per mouse in Figure 5C.  In addition, the 
quantification results were able to statistically distinguish at a group level between the control 
limb and the lesion limb groups (p<0.0001).  
In vivo microCT can be utilized to track changes in a drug treatment model 
As described above, we treated mice with zoledronic acid starting at week 1 (when 
lesions were detectable) and imaged the mice weekly.  With this approach we found that we 
could determine bone volumes for the treatment and control limbs in all mice, as well as 
quantify changes between the  treated versus untreated groups by in vivo microCT (Figure 6A-
D).  Figure 4A and 4B demonstrate the ability to register weekly scans at end-point and 
determine average bone volume for treatment groups, as graphed per mouse and by groups in 
Figure 6C and 6D.  There was no statistical significance (p=0.0443) between the mean bone 
volume of zoledronic acid treated tumor and non-tumor limbs, but there was a significant 
difference between the treated and untreated lesion limbs (p<0.0001).  Interestingly, with this 
approach we could also see a statistical increase in the mean bone volume of the non-tumor 
limb when treated with zoledronic acid (p<0.0001).    
  
 Figure 5.  In vivo microCT allows for quantifiable longitudinal images of tumor
destruction.  (A) Isosurface volume renderings of the control limb from a representative mouse 
at weeks 1 (blue), 2 (green), 3 (red), and 4 (tan), after intratibial sham PBS injecti
Isosurface volume renderings of the tumor
weeks 1, 2, 3, and 4 after intratibial inoculation of MDA
rendering is shown for both the control (A, large panel) 
combining all four time points. All rendering thresholds were set to 1000 HU. (C) Bone volume 
was determined for each mouse at each time point (weeks 1, 2, 3, and 4) in both the control and 
tumor-bearing limbs. 
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-bearing limb from the same representative mouse at 
-MB-231 cells. In addition, a registered 
and tumor-bearing (B, large panel) limbs 
-induced bone 
on. (B) 
 Figure 6.  In vivo microCT monitors changes in bone volume when mice are treated with 
zoledronic acid.  (A) Isosurface volume renderings of the zoledronic acid treatment group at 
weeks 1 (tan), 2 (yellow), 3 (red), and 4 (blue), afte
volume renderings of the zoledronic acid treatment group at weeks 1, 2, 3, and 4 after intratibial 
inoculation of MDA-MB-231 cells. In addition, a registered rendering is shown for both the 
control (A, large panel) and tumor
rendering thresholds were set to 1000 HU. (C) Bone volume was determined for each mouse at 
each time point (weeks 1, 2, 3, and 4) in both the control and tumor
the mean group volume and standard deviation over time for both the tumor
control limb of the zoledronic acid and control groups.
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well as (D) 
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Conventional imaging methods demonstrate comparable bone volume to in vivo microCT 
In order to validate the in vivo microCT quantification method we directly compared 
these results to ex vivo microCT (Figure 7A) and BV/TV results calculated from histological 
analyses (Figure 7B), and we found that the quantification of bone volume by ex vivo microCT 
and histomorphometry was comparable to in vivo microCT.  We also found that while 
histological analyses were higher resolution than the longitudinal CT, we could obtain 
comparable results with lower resolution scans, and more importantly we could examine the 
progression of lesions in a single mouse over time with in vivo microCT.  The tumor volume was 
found to be significantly decreased in bisphosphonate-treated mice by histology, which we 
believe is due to enhanced bone growth since it is not clear whether bisphosphonates can 
directly affect tumor cells.  In vivo microCT bone volume computations were comparable to 
Faxitron data longitudinal analysis of lesion area and number (Figure 7C), and we confirmed that 
tumor cell fluorescence persisted throughout the duration of the study (Figure 7D). 
Conclusions 
In a model of breast cancer metastasis to bone, we found that in vivo microCT is a useful 
method for quantifying 3-dimensional longitudinal osteolysis without killing tumor cells, and is 
comparable to conventional methods of bone analysis such as ex vivo microCT, Faxitron analysis, 
and histomorphometry.  In addition, we found that this method of in vivo microCT is 
reproducible and can detect significant changes in bone volume in a pre-clinical drug treatment 
model, suggesting its potential utility in blastic models of prostate cancer metastasis to bone.  
Further optimization of this protocol may also be useful in distinguishing changes in cortical and 
trabecular bone volume in vivo. 
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Taken together, these data indicate that in vivo microCT is an effective and reproducible 
method for longitudinal monitoring of tumor-associated bone destruction in mouse models of 
tumor-induced bone disease.  However, due to its low throughput, its practicality in evaluating 
osteolytic bone disease in large-scale studies is not optimal, and therefore we utilized 
conventional imaging methods such as Faxitron and fluorescence to monitor tumor growth and 
bone destruction in our later studies, and ex vivo microCT to determine bone volume at end-
point.   
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Figure 7.  Conventional imaging methods are comparable to in vivo microCT bone volume 
analysis of zoledronic acid treatment mice.  (A) Ex vivo microCT analysis demonstrates a 
significant difference in bone volume between the treated and untreated tumor-bearing limbs, 
similar to the group analysis by in vivo microCT in Fig. 4C. Representative images of control and 
tumor-inoculated hind limbs with and without zoledronic acid treatment demonstrate the 
rescue of bone volume in tumor-bearing limbs with bisphosphonate treatment. (B) Histological 
analyses indicate a significant increase in bone volume in tumor-bearing limbs of mice treated 
with zoledronic acid, further validating the data generated by in vivo microCT. Similar to the in 
vivo microCT, histomorphometry did not indicate any difference in bone volume in the control, 
nontumor limbs of mice treated with zoledronic acid or PBS. Black bars represent a length of 
500 μM. (C) Faxitron images demonstrate tumor-associated osteolysis at week 4 in tumor-
bearing mice treated with either PBS (left panel) or the zoledronic acid (right panel). White 
arrows indicate representative osteolytic lesions in bone. X-ray analyses indicate a decrease in 
lesion area in mice treated with zoledronic acid versus PBS, consistent with both ex vivo and in 
vivo microCT (bottom, left graph). Lesion number by Faxitron analyses is also decreased in mice 
treated with zoledronic acid versus PBS (bottom, right graph). (D) Tumor burden was monitored 
by tumor cell fluorescence utilizing Cri Maestro throughout the drug treatment study. Mice 
treated with zoledronic acid exhibited significantly smaller tumors at week 4 than control mice 
treated with PBS. Columns indicate average group values, and error bars represent standard 
error (SE). P values are represented respectively for each graph, and statistical significance is 
considered p<0.05. 
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Tgf-β promotion of Gli2-induced expression of PTHrP is independent of canonical Hh signaling 
Introduction 
Breast cancer metastasis to bone begins with initiation of the vicious cycle of bone 
destruction, commencing upon tumor cell establishment in the bone marrow and resulting in 
increased bone resorption, or osteolysis.  Tumor cells receive signals from the bone marrow 
environment (e.g. Tgf-β), which up-regulates expression of the Hh signaling transcription factor, 
Gli2, and leads to increased production of osteolytic factors such as PTHrP (26).  PTHrP 
propagates the vicious cycle via PTH-receptor binding on osteoblasts, leading to increased Rankl 
expression, which induces osteoclastogenesis.  As the bone is resorbed, active Tgf-β is released 
from the bone matrix stimulating further tumor growth and PTHrP production (35). 
 Given the nature of the vicious cycle, inhibition at any point in this process should 
reduce bone destruction.  For example, neutralizing antibodies against tumor production of 
PTHrP inhibits osteolytic bone destruction and tumor burden in vivo (28, 239).  While a 
humanized anti-PTHrP antibody was developed in 2003, no official report has been made about 
the success of this antibody in patients (240, 241).   Our laboratory has previously demonstrated 
that the Hh signaling transcription factor Gli2 positively regulates PTHrP expression and 
secretion in osteolytic breast tumor cells (36). 
Gli protein activation has been demonstrated in numerous tumor types and results from 
a variety of mutations that occur throughout the Hh signaling pathway (66).  In these tumor 
types, Hh receptor antagonists like cyclopamine have been used successfully to prevent Gli over-
expression (230).  While all Gli family members bind to the same binding sequence, they have 
separate and discrete functions in mammalian cells (242).  Our group has shown that Gli2, but 
not the other Gli family members, enhances PTHrP expression.  Furthermore, expression of Gli2 
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appears limited to tumor cells that have high metastatic potential, especially to bone resulting in 
osteolytic lesions (36).   
Taken together, these data suggest that inhibition of Gli2 is a potential target for the 
development of therapeutics aimed at preventing and treating bone metastases. Therefore, we 
hypothesized that inhibition of Gli2 in bone metastatic lines would decrease PTHrP expression 
and cause a reduction in osteolytic lesions.   
Cyclopamine treatment does not prevent tumor-induced bone destruction in vivo 
Cyclopamine treatment has previously been reported to block Hh signaling and inhibit 
tumor growth in some in vivo models (67) through its action as a Smo antagonist (68).  
Therefore, we first proposed to determine the effects of cyclopamine treatment on osteolytic 
bone metastases.  Mice inoculated with MDA-MB-231 human breast cancer cells were treated 
with 10mg/kg cyclopamine or control tomatadine analog daily, beginning two weeks post-
inoculation and after tumor cells had seeded to bone, similar to previously published treatment 
regimens which successfully inhibited tumor growth (243).  Surprisingly, cyclopamine inhibited 
neither tumor growth nor cancer-induced bone disease in the bone metastasis model.  Indeed, 
examination by radiography (Figure 8A) indicated that there was a slight increase in osteolytic 
lesion number in mice treated with cyclopamine when compared to tomatadine-treated mice.  
After sacrifice, bones were collected from tumor bearing mice from both treatment and control 
groups for histology and histomorphometry.  Histologically, cyclopamine treatment had little or 
no effect on tumor burden in bone (Figure 8B) or trabecular bone volume at multiple sites 
commonly examined by histology (Figure 8C).   It was concluded that the Hh receptor antagonist 
cyclopamine is ineffective treatment for osteolytic bone metastases in this experimental model 
of breast cancer-induced bone destruction. 
 Figure 8.  Cyclopamine does not reduce osteolysis or tumor burden.
with 10 mg/kg of cyclopamine (
radiographically weekly. (A) Faxitron analyses indicate no significant difference (ns) in lesion 
number in cyclopamine-treated versus nontreated mice. There was
(B) tumor burden detected by % tumor area, or (C) bone volume measured as trabecular BV/TV, 
on histomorphometric analyses of H&E
represents a length of 500 μm. Values
unpaired t test.  *p < 0.05; **
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Many tumor types have mutations that lead to a constitutive activation of Gli proteins, 
demonstrating a clinical need for identifying targets to inhibit this pathway.  Current therapeutic 
approaches focus primarily on the development of Smo antagonists, such as cyclopamine 
analogs.  However, our data suggest that at least in some cancers, cyclopamine analogs are 
unlikely to be effective in blocking tumor-induced osteolysis. 
Canonical Hh signaling does not regulate GLI2 in MDA-MB-231 cells 
To determine why MDA-MB-231 breast cancer cells are not inhibited by cyclopamine, 
we next examined the expression of Hh signaling receptors.  MDA-MB-231 cells, which express 
both GLI2 and PTHrP and are known to cause osteolysis, did not express SMO mRNA, and MCF-7 
breast cancer cells (non-osteolytic) and RWGT2, a squamous non small cell lung carcinoma cell 
line, expressed low levels of SMO mRNA (Figure 9A).  In contrast, PC-3 prostate cancer cells 
were found to express SMO mRNA, consistent with findings by another group that showed 
these cells are inhibited by cyclopamine (Figure 9A) (230).   
Treatment of MDA-MB-231 cells with cyclopamine in vitro did not alter tumor cell 
growth over a 7-day treatment period (Figure 9B), indicating that Hh signaling does not play a 
significant role in the growth of these cancer cells.  We next examined cyclopamine-treated 
MDA-MB-231 and RWGT2 cells for PTHrP and Gli2 expression by Q-PCR.  As a positive control, 
we also tested the cyclopamine-treated chondrocyte cell line, TMC-23, which expresses SMO 
and is responsive to cyclopamine.  Blocking Hh signaling had no effect on PTHrP mRNA 
expression in either of the tumor cell lines, and cyclopamine treatment did not inhibit and in 
fact increased GLI2 mRNA in both the MDA-MB-231 and RWGT2 cells (Figure 9D&E). Since Hh 
signaling is known to regulate PTHrP expression in proliferating chondrocytes (244), we 
reasoned that TMC-23 cells would be inhibited by cyclopamine, and as expected, PTHrP 
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expression was indeed inhibited by cyclopamine treatment in TMC-23 cells (Figure 9C).  
Together, these data confirm that the compound was active and suggests that osteolytic tumor 
cells rely on an alternative mechanism for PTHrP expression.   Thus, Hh signaling inhibition by 
cyclopamine appears ineffective towards breast tumor cell growth or expression of osteolytic 
factors by tumor cells, and we concluded that elevated GLI2 expression levels in MDA-MB-231 
cells is not due to enhanced Hh signaling through the canonical pathway.   
Our data indicate that several osteolytic tumor cell lines, including human breast cancer 
MDA-MB-231 cells, either do not express SMO or express it at very low levels, providing an 
explanation for the observed failure of cyclopamine to inhibit PTHrP expression or tumor-
induced bone disease.  In light of this data, the expression levels of Hh receptors SMO and PTCH 
would have been useful prior to in vivo studies.  However, it is generally assumed that elevated 
Gli expression is mediated primarily via upstream Hh receptor activation.  Although Smo-
independent mechanisms have been described in prostate cancer (24), this is the first report 
with regards to bone metastases of Gli over-expression mediated via a Smo-independent 
mechanism.  Surprisingly, we found that cyclopamine treatment actually increased GLI2 
expression, though these results were not significant in some osteolytic tumor cells.  While the 
mechanism of this increase remains unclear, Zhang et al reported that cyclopamine has ‘off-
target’ effects on other signaling pathways (245).  In addition, other groups have reported that 
cyclopamine impacts normal bone marrow cell compartments (246-250).  Since cyclopamine 
had no significant effect on overall bone disease in our model, it is unlikely that the compound 
had any effect on other cells in the bone-tumor micro-environment.  However, since duration of 
treatment in our experiments was relatively short, we cannot rule out that longer-term 
treatments may alter cells within the bone marrow. 
 Figure 9.  Gli2 is regulated by a Hedgehog independent mechanism.
and Smo receptor expression in osteolytic and nonosteolytic cell lines show MDA
do not express Smo. (B) MDA
significant (ns) difference in tumor cell growth by M
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examined after 24 hours for GLI2 and PTHrP mRNA expression by Q
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These data suggest that Smo antagonists are unlikely to be effective and may even have 
detrimental effects in some cases of tumor metastasis to bone.  It will be necessary to establish 
how commonly breast and other bone-metastasizing cancers are deficient in Smo expression.  
Our data indicate that Gli2 is regulated independent of Hh signaling in osteolytic tumor cells, 
allowing us to bypass the Hh signaling pathway altogether, and we therefore looked to 
alternative signaling pathways known to regulate GLI2 transcription and its downstream targets. 
Tgf-β regulation of Gli2 signaling in human osteolytic breast cancer cells 
Since Tgf-β is known to regulate PTHrP, and other groups have shown that Tgf-β 
regulates GLI2 expression in hepatocarcinoma cells (60), we set out to determine if Tgf-β 
stimulates GLI2 expression in osteolytic tumor cells.  MDA-MB-231 cells were tested to 
determine if Tgf-β enhances GLI2 mRNA expression following treatment with 5ng/mL 
recombinant human Tgf-β for 48 hours.  Consistent with previous studies in other cell types, Tgf-
β significantly enhanced GLI2 and PTHrP mRNA expression (Figure 10A) in MDA-MB-231 cells by 
Q-PCR.  As expected, Tgf-β also increased PTHrP protein secretion (Figure 10B).  We have found 
similar results when cells were treated with Tgf-β up to 24 hours (data not shown).  These data 
indicate that Tgf-β, in addition to regulating PTHrP production, may also regulate Gli2 in 
osteolytic tumor cells; however, the necessity of Gli2 for TGF-β effects on PTHrP remains 
unclear. 
In order to determine if Gli2 is required for Tgf-β to stimulate PTHrP, MDA-MB-231 cells 
were stably transfected with an empty vector control or Gli2-Repressor construct (Gli2-Rep) in 
which the activation domain of the GLI2 promoter has been replaced with the engrailed 
repressor domain as previously described (227), resulting in effective  blockade of GLI2 
transcription.  We have found that this construct efficiently knocks down Gli2 activity in vitro  
 Figure 10.  Tgf-β stimulates GLI2 and PTHrP production.
increases significantly in MDA
supplemented with 5 ng/mL recombinant Tgf
expression (right) increases in MDA
stimulation with 5 ng/mL Tgf
cells.  Values = mean ± SE, and 
0.01, ***p<0.001. 
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(36).  After generating stable cell lines, positive cells were selected based on neomycin 
resistance, with both single cell clones and pools of transfectants generated.  Because of 
concerns that single cell clones may result in a selection of a population with a constitutive 
decrease in PTHrP or a decrease or increase in aggressiveness, we focused on the pooled 
populations for these studies.  However, similar results were obtained for all populations tested.  
Positive cells were screened for the expression of Gli2-Rep with an anti-His-tag antibody by 
Western blot (Figure 11A).  Consistent with our previous observation that Gli2 stimulates PTHrP 
expression, the expression of Gli2-Rep caused a reduction in endogenous PTHrP mRNA 
expression in MDA-MB-231 cells (Figure 11B).  Interestingly, expression of Gli2-Rep had no 
effect on tumor cell growth in vivo when cells were injected orthotopically into the mammary 
fat pad of athymic nude mice (Figure 11C).   
Following successful transfection, stable pooled MDA-231-Gli2-Rep cells were treated 
with 5ng/ml recombinant human Tgf-β1 in serum-free medium and evaluated for PTHrP mRNA 
expression.  We found that the Gli2-Rep construct significantly blocked the ability of Tgf-β to 
induce PTHrP mRNA expression (Figure 12A), indicating that Gli2 is necessary for TGF-β 
stimulation of PTHrP.  Importantly, basal PTHrP mRNA expression in MDA-MB-231 cells was not 
affected by Gli2 inhibition when cells were grown in serum free medium in Figure 12A, as 
compared to its effect on cells grown in 10% fetal bovine serum containing biologically active 
Tgf-β in Figure 11B.  Our data suggest that directly targeting Gli2 may attenuate TGF-β induction 
of PTHrP, and thereby abrogate subsequent PTHrP-mediated bone destruction. 
To further clarify the role of Gli2 in the Tgf-β-PTHrP signaling axis, and to determine 
whether Gli2 acts downstream of Tgf-β signaling to regulate PTHrP in MDA-MB-231 cells, we 
disrupted the Tgf-β signaling pathway by stable expression of a dominant negative TGF-β  
 Figure 11.  Gli2-Rep inhibits PTHrP production, but not tumor growth.
MDA-MB-231 cells transfected with the Gli2
were examined by (A) Western blot to verify efficient expression of Gli2
Gli2-Rep cells grown in culture medium supplemented w
mRNA expression by Q-PCR have reduced PTHrP mRNA expression.  (C) MDA
(n = 8) or MDA-MB-231-cntrl (
sacrificed after 3 weeks to determine tumor cell growth 
values were determined using unpaired 
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receptor type II (DNRII) construct in the MDA-MB-231 cells, as previously published (69).    When 
Tgf-β signaling was abolished in this way, both GLI2 (Figure 12B) and PTHrP mRNA expression 
(Figure 12C, right panel) were significantly decreased.  These data suggest that GLI2 inhibition 
impairs the ability of Tgf-β to stimulate PTHrP production, resulting in abrogation of tumor-
induced bone destruction.  Additionally, over-expression of Gli2 protein in the MDA-231-DNRII 
cells resulted in a dramatic increase in PTHrP promoter activation (Figure 12C, left panel), and a 
partial rescue of PTHrP mRNA expression (Figure 12C, right panel), further suggesting that Gli2 
expression is downstream of Tgf-β signaling.  We therefore conclude that the stimulatory effect 
of Tgf-β on PTHrP expression is likely to be mediated through Gli2. 
Tgf-β inhibition decreases PTHrP activity 
 Since our data strongly indicate that Tgf-β stimulates Gli2 and PTHrP production, and 
previous data has shown that Tgf-β inhibition in vivo provides bone anabolic effects (12, 13), we 
reasoned that Tgf-β inhibition would likely inhibit PTHrP in vitro.  Accordingly, when we treated 
MDA-MB-231 cells with the Tgf-β neutralizing antibody, 2G7, we found that PTHrP promoter 
activity was significantly decreased (Figure 13).  Our group has since moved in vivo with Tgf-β 
neutralizing antibodies in mouse models of breast cancer metastasis to bone, where mixed 
results were observed.  It appears that Tgf-β inhibition blocks tumor-induced bone disease when 
given at the time of tumor cell inoculation, but is less effective at blocking bone disease in more   
established tumors (Biswas et al., unpublished data).  These studies are on-going, but even if 
successful in blocking tumor burden, the use of Tgf-β inhibitors to block bone disease clinically 
could have detrimental effects on patients with residual primary tumor (216).  Genetic mouse 
models have shown that when TGF-β is activated, it is protective against tumor growth at the 
primary site, but at later stages of disease it can promote metastasis (216).   
 Figure 12.  Tgf-β regulates GLI2 expression, which is required for PTHrP stimulation.
231-cntrl or MDA-231-Gli2
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Conclusions 
These studies indicate that Gli2 is regulated independent of Hh signaling in some 
osteolytic tumor cells, specifically human MDA-MB-231 breast and RWGT2 non-small cell lung 
carcinoma cells.  These data are important considering the current clinical emphasis on pursuing 
Smo antagonists for the treatment of primary cancer.  We also show that although Gli2 lacks 
regulation through the Hh signaling pathway, Tgf-β signaling, which is known to regulate PTHP 
production, stimulates GLI2 mRNA expression and requires Gli2 for its stimulatory effects on 
PTHrP.  In combination, these data indicate that Tgf-β inhibition would likely be beneficial in 
blocking Gli2 and PTHrP-induced bone destruction.  Although in vitro studies confirm decreased 
PTHrP promoter activity, the in vivo studies are in progress and require further analysis in 
multiple tumor types.  However, the biphasic role of Tgf-β in primary and metastatic breast 
cancer suggests that alternative pathways regulating Gli2 should be explored. 
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Bone stiffness drives Wnt signaling regulation of Gli2 in osteolysis 
Introduction 
Upon metastasis to bone, breast tumor cells up-regulate the expression of the 
transcription factor GLI2, which directly stimulates the expression and secretion of PTHrP into 
the tumor-bone micro-environment (251).  The release of PTHrP and other osteolytic factors 
activates osteoclasts and stimulates bone resorption, enabling the release of active Tgf-β from 
the mineralized bone matrix (26, 251).  Previous reports have indicated that Tgf-β positively 
regulates tumor-derived Gli2 and PTHrP expression (61, 69, 76), and stimulates tumor cell 
proliferation in bone (26).  
In addition to Tgf-β, it is well established that matrix stiffness impacts tumor cell 
evolution at the primary site of disease (252-254), and there is increasing evidence that matrix 
rigidity has a significant impact on tumor cell behavior in the mineralized bone micro-
environment (95, 251).  Indeed, our group has reported that the structural components of bone 
enhance tumor cell gene expression of GLI2, PTHrP, and TGF-β1 ligand (97) through 
mechanotransduction, suggesting that bone stiffness and the Tgf-β signaling pathway are 
significantly linked and may play an important role in the establishment and initiation of tumor-
induced osteolysis.   
Published reports of the GLI2 promoter identified a SMAD-binding element (SBE) and 
TCF-binding element (TBE) in a regulatory region upstream of the transcription initiation site in 
keratinocytes (60), suggestive of both Tgf-β and Wnt regulation of Gli2 signaling. Recent data 
has also linked the Wnt signaling pathway with mechanotransduction and the Src family kinases.  
For example, Previdi et al showed that phospho-Src and β-catenin co-localize in the nuclei of 
bone-metastatic breast tumor cells (255), and other groups have indicated that c-Src may 
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phosphorylate β-catenin (256, 257).  Additional work has shown that Wnt inhibition blocks 
phospho-wbp2-mediated breast tumor cell growth, which is a phosphorylation target of c-Src 
(258).  Furthermore, a lack of β-catenin nuclear accumulation in association with E-cadherin 
down-regulation in breast and colon cancer has been demonstrated in a subset of brain 
metastases (259), and non-canonical Wnt signaling has been identified as a key regulator of 
brain metastatic breast cancer cells (260).   
Since we have previously shown that Tgf-β signaling is an upstream regulator of Gli2 in 
osteolytic breast cancer cells (61), we hypothesized that Wnt signaling may also regulate Gli2 in 
bone metastatic breast cancer cells, and furthermore, that this effect is influenced by the rigidity 
of bone.  Our data presented here indicate that downstream Wnt signaling molecules facilitate 
GLI2 and PTHrP up-regulation, and that downstream Wnt signaling is activated when tumor cells 
are exposed to stiff substrates similar to the rigidity of bone. 
Stiffness causes alterations in Wnt signaling which lead to GLI2 and PTHrP activation 
Previous studies have shown that Wnt signaling and mechanotransduction are linked at 
the nuclear level (255, 258) through Src kinase activity, and our group has previously published 
that the rigidity of bone enhances Gli2 and PTHrP expression through alterations in Tgf-β 
signaling (95, 97).  We therefore reasoned that stiffness may also influence Wnt signaling 
upstream of Gli2 and PTHrP.  To test this, MDA-MB-231 cells were seeded onto substrates 
representative of soft breast tissue [polyacrylamide (PA) gel containing fibronectin (Fbn) to 
facilitate cell attachment] or stiff trabecular bone [tissue culture polysterene (TCPS) + Fbn], as 
previously published (97), and Wnt signaling activation was examined by transfecting MDA-MB-
231 cells with a TOPFlash reporter for TCF activity.  We found that MDA-MB-231 cells plated on 
the stiff TCPS or TCPS+Fbn exhibited a 7-fold increase in TOPFlash activity when compared to 
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cells plated on PA gels (Figure 14A), indicating enhanced β-catenin signaling through T-cell factor 
(TCF).  In addition, MDA-MB-231 cells seeded onto TCPS exhibited overall greater Wnt signaling 
activity in a Wnt Signaling PCR-based microarray (SABiosciences) through enhanced expression 
of numerous Wnt signaling molecules (Table 1), primarily downstream of the Wnt ligands. 
To verify that the enhancement of downstream Wnt signaling on TCPS resulted in 
functional translocation of β-catenin to the nucleus of MDA-MB-231 cells, we examined β-
catenin expression by Western blot in nuclear and cellular fractions of cells plated on TCPS, TCPS 
+ Fbn and PA gels.  Cells seeded onto TCPS or TCPS + Fbn showed abundant β-catenin expression 
in both cytosolic and nuclear fractions, while cells seeded onto PA gels exhibited approximately 
57% less nuclear β-catenin as calculated by region of interest (ROI) analysis and when compared 
to the cytosolic fraction (Figure 14B, results representative of n=3).   
Based on previous data implicating Wnt signaling in bone mechanotransduction and 
crosstalk with Src kinase (255-258), its role in mechanical bone loading (261, 262), and our 
observation that TCF activity downstream of Wnt signaling was enhanced on stiff substrates, we 
wanted to determine if this was due to an accumulation of nuclear β-catenin, or through some 
other mechanism.  Our Western analyses in Figure 14B indicated that cells seeded onto soft 
substrates contain less nuclear β-catenin, which correlates nicely with previously published data 
showing that β-catenin is localized to the nucleus of bone metastatic MDA-MB-231 cells plated 
on standard TCPS by immunofluorescence (255).  Unfortunately, direct confirmation of these 
data are not possible; the nature of the PA gels prevents accurate visualization of the cytoplasm 
and nucleus, the process of fixation alters the structure of the PA gel, and the gel itself auto-
fluoresces.  It should also be noted that although MDA-MB-231 cells normally express relatively  
  
 Figure 14.  Stiffness activates Wnt signaling and induces nucl
MDA-MB-231 cells were transfected with TOPFlash reporter construct and evaluated for TCF 
activation by dual-luciferase reporter assay system (n=3/column).  (B)  MDA
seeded onto stiff substrate (TCPS), stiff su
substrate containing Fbn to facilitate cell attachment (PA gel) were harvested for cytoplasmic 
and nuclear protein fractions and examined for β
(representative of n=3).  Values = mean ± standard error, and p
unpaired t-test.  *p< 0.05, **p< 0.01, ***p<0.001.
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low levels of β-catenin (260), the process of nuclear fractionation causes protein enrichment, 
making it appear in Figure 14B that endogenous β-catenin is abundant. 
Interestingly, β-catenin accumulation in the nucleus and enhanced Wnt signaling activity 
on stiff substrates hold implications for the way we currently study osteolytic tumor cells and 
changes in mRNA gene expression.  Indeed, the stiff substrate we utilize to represent trabecular 
bone in these experiments is tissue culture polysterene (TCPS), which is the standard material 
used for plating cell culture-based assays.   This suggests that our bone-seeking strain of 
osteolytic tumor cells is already in its “active” or bone-altered state in normal assays.  
Accordingly, culturing parental MDA-MB-231 cells onto TCPS does not make them as aggressive 
as a bone seeking clone, which suggests that the rigidity of bone may only affect tumor cell 
behavior once it has metastasized to bone and may not affect tumor cell expression prior to 
metastasis. 
GLI2 and PTHrP expression and activity are responsive to downstream Wnt signaling 
Recent publication of the GLI2 promoter in keratinocytes and hepatocarcinoma cells 
revealed that in addition to Hh signaling, the GLI2 transcription factor can be regulated through 
a combination of downstream Tgf-β and Wnt signaling molecules, namely Smad2/3 and the co-
factor for β-catenin, T-cell factor (TCF) (60).  These molecules bind a SMAD-binding element 
(SBE) and TCF-binding element (TBE) located within the regulatory region of the GLI2 promoter 
(60).  Given the location of these binding elements, we proposed that Gli2, which is up-regulated 
in osteolytic breast tumor cells (36), may also be regulated via the Tgf-β and Wnt signaling 
pathways.  Wnt signaling alterations have been implicated in a number of different cancers  
(263-268), and we have previously shown that Tgf-β signaling does in fact regulate Gli2 
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expression in osteolytic tumor cells (61).  In combination, these data suggest that Wnt signaling 
may also influence Gli2 expression in osteolysis.   
To determine the effect of enhanced Wnt signaling in osteolytic tumor cells on Gli2 
expression, MDA-MB-231 cells, which normally express low levels of β-catenin even when 
plated on TCPS (260), were transiently co-transfected with a non-degradable form of β-catenin 
and its co-factor TCF4.  We found that over-expression of β-catenin/TCF4 resulted in an up-
regulation of GLI2 mRNA expression by Q-PCR, and significantly activated the Wild-type (WT) 
GLI2 promoter (Figure 15A&B).  When we looked at factors downstream of Gli2, we found that 
PTHrP promoter activity was enhanced when β-catenin was over-expressed (Figure 15C).  Since 
β-catenin functions downstream of Wnt signaling, we also stimulated upstream Wnt signaling by 
LiCl treatment, which has been previously reported to up-regulate the Wnt signaling pathway by 
inhibiting GSK3-β phosphorylation of β-catenin (229).   LiCl treatment was added at a dosage of 
20mmol (228, 229)and 40mmol (228) as previously published, where we observed a significant 
increase in both GLI2 (approx. 295-fold) and PTHrP (approx. 2,000-fold) mRNA expression 
(Figure 16A&B) at 40mM only (20mmol not shown) and a trend toward promoter activation 
(results not significant) (Figure 16C&D).     
Given the extent of GLI2 and PTHrP up-regulation following LiCL treatment, it is possible 
that other molecules stimulated by LiCl treatment may also affect GLI2 and PTHrP mRNA 
transcription or stability.  Interestingly, we were unable to inhibit GLI2 or PTHrP mRNA 
expression or activity by blocking Wnt signaling with small molecule inhibitors XAV939 or VU-
WS113, even if we first stimulated their expression with recombinant TGF-β treatment (Figure 
17B).  MDA-MB-231 cells were also tested in serum-free conditions with similar results (Figure 
17A).  XAV939 abrogates Wnt signaling by stabilizing axin and promoting β-catenin degradation  
 Figure 15.  Effects of constitutive β
MDA-MB-231 cells co-transfected with constitutively expressed β
co-factor TCF4 were evaluated for GLI2 mRNA expression (n=3/column).  Da
18S eukaryotic rRNA.  MDA
wild-type (WT) GLI2 promoter (B), or PTHrP promoter (C) (n=3/column).  Values = mean ± 
standard error, and p-values were determined using unpair
***p<0.001. 
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  (A)  
 Figure 16.  LiCl treatment stimulates GLI2 and PTHrP mRNA expression and promoter 
activation.  MDA-MB-231 cells were treated for 24 hours with vehicle (water), 20mM, or 40mM 
LiCl solution to stimulate Wnt signaling through GSK3
GLI2 mRNA expression and (B) PTHrP mRNA expression (n=3/column).  Both sets of data are 
normalized to 18s eukaryotic rRNA.  MDA
promoter (D) were harvested for luciferase assay following 24 hour LiCl treatment 
(n=3/column).  Values = mean ± standard error, and p
test.  *p< 0.05, **p< 0.01, ***p<0.001.
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through tankyrase inhibition (269), and VU-WS113 is a pyrvinium analogue developed by Ethan 
Lee’s lab at Vanderbilt, which antagonizes Wnt signaling by enhancing CK1 activity, an enzyme 
partly responsible for β-catenin phosphorylation and its subsequent degradation (270).  
Although initially surprised by these data, we believe that the lack of inhibition of GLI2 and 
PTHrP mRNA expression may be contributed to up-regulated proteasome activity in our tumor 
cells, which is apparent in our Wnt signaling PCR microarray data in Table 1, or an indication of 
alternative regulators of β-catenin.   
Since we observed elevated Gli2 and PTHrP expression when Wnt signaling was 
enhanced, and direct inhibition of Wnt signaling was ineffective in blocking GLI2 or PTHrP mRNA 
expression, we explored an alternative method of Wnt signaling inhibition and the effect on 
gene expression.  Since MDA-MB-231 cells express relatively low levels of β-catenin (260), as 
well as low levels of Gli2 and PTHrP in the absence of Tgf-β (36), we reasoned that it may be 
difficult to block endogenous Gli2 and PTHrP through knockdown of β-catenin.  However, MDA-
MB-231 cells express high levels of the Wnt signaling antagonist, Dkk1 (271), which is also a 
downstream target of Wnt signaling.  Therefore, we proposed that knockdown of DKK1 would 
result in elevated GLI2 and PTHrP mRNA expression.    To test this, MDA-MB-231 cells were 
transiently transfected with shRNA against β-catenin (CTNNB1) or DKK1 and examined for GLI2 
and PTHrP expression in the presence or absence of recombinant human TGF-β.  As anticipated, 
we found that CTNNB1 knock-down was not sufficient to inhibit endogenous levels of GLI2 even 
in the presence of excess Tgf-β, but when we knocked down DKK1 in MDA-MB-231 cells, GLI2 
and PTHrP mRNA expression were significantly enhanced (Figure 18A&B).    
The basal expression of Gli2 and PTHrP in MDA-MB-231 cells, although higher than in 
tumor cells which do not cause osteolytic bone destruction in vivo (36), is relatively low in the  
 Figure 17.  Wnt small molecule antagonists do not consistently inhibit GLI2 or PTHrP 
expression.  MDA-MB-231 cells were treated for 24 hours with 100nmol
(control), XAV939, or VU-WS113 to block Wnt signaling and harvested for RNA.  (A) GLI2 and (B) 
PTHrP mRNA expression were evaluated by Q
values were determined using unpaired t
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 Figure 18.  DKK1 knockdown up
cells transfected with shRNA against β
as a control.  Recombinant human Tgf
following transfection.  (A) GLI2 mRNA expression and (B) PT
normalized to 18S eukaryotic rRNA (n=3/column).  Values = mean ± standard error, and p
were determined using unpaired t
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absence of Tgf-β.  Therefore, inhibitors of their endogenous expression are difficult to find, and 
we are generally able to enhance Gli2 and PTHrP production more efficiently than inhibiting 
their expression.  Since MDA-MB-231 cells have previously been shown to express low levels of 
β-catenin (260) and elevated levels of Dkk1 (271), we reasoned that knockdown of CTNNB1 
would likely not affect Gli2 and PTHrP, while knockdown of DKK1 would enhance Gli2 and 
PTHrP.  As anticipated, CTNNB1 knockdown did not affect GLI2 or PTHrP mRNA expression, 
despite our data showing that β-catenin over-expression significantly enhanced Gli2 
transcription.  Accordingly, knocking down DKK1 enhanced GLI2 and PTHrP expression.  It is 
important to note that the publication citing Dkk1 levels in MDA-MB-231 cells to be >78-fold 
higher than in MCF-10A cells (271) conducted these experiments when MDA-MB-231 cells were 
cultured on TCPS, making it difficult to determine the contribution of matrix stiffness to the 
endogenous levels of Dkk1. 
Effects of Wnt and Tgf-β signaling on mRNA stability 
Since our group has demonstrated that Tgf-β signaling regulates GLI2 mRNA expression 
in osteolytic tumor cells (61) and since the knockdown of DKK1 enhanced GLI2 expression only 
when Tgf-β was in excess, we examined whether Tgf-β or β-catenin affects GLI2 mRNA stability.  
MDA-MB-231 cells were either transfected with non-degradable β-catenin or treated with 
5ng/ml human recombinant Tgf-β1 and incubated with 0.8μM actinomycin D to block 
transcription over a period of 10 hours.  The cells were harvested for RNA at multiple time 
points and examined for GLI2 mRNA expression by Q-PCR.  Using Linear Regression analysis and 
slope comparison, we found that neither Tgf-β alone, nor Tgf-β in combination with β-catenin 
over-expression, significantly altered GLI2 mRNA stability (Figure 19A). 
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Recombinant human Tgf-β1 was added to the culture medium in these experiments, as 
indicated, to more accurately reflect the physiological environment of the tumor cells within 
rapidly resorbing bone matrix, which is an abundant source of Tgf-β (26).  Since the up-
regulation of GLI2 following DKK1 knockdown was achieved in conditions with excess Tgf-β, we 
thought it likely that Tgf-β was stabilizing the GLI2 transcript; however, when we attempted to 
rescue GLI2 transcription with Tgf-β, it was unable to stabilize GLI2 mRNA, suggesting that in 
addition to β-catenin regulation of Gli2, Wnt signaling may crosstalk with other signaling 
pathways in MDA-MB-231 cells, such as Src kinase.  Our group is currently investigating the 
effects of Src kinase as a function of mechanotransduction on Gli2 and PTHrP regulation 
(Ruppender et al.; submitted).  It is possible that a combination of lifting the “brakes” on the 
Wnt signaling pathway through Dkk1 inhibition and adding excess Tgf-β results in optimal GLI2 
transcription conditions in MDA-MB-231 cells, but it is unlikely that this is due to mRNA 
stabilization.  These data correlate nicely with the results published by Dennler and colleagues 
on Tgf-β activation of the GLI2 promoter in keratinocytes (60). 
Previous reports have suggested that Tgf-β signaling plays a crucial role in regulating 
PTHrP mRNA stability (75-77); however, there are conflicting published data concerning Tgf-β 
regulation of PTHrP mRNA stability (78), and these data remain controversial to some extent.  
To determine the dual effect of Tgf-β and Wnt signaling on PTHrP mRNA stability, we again 
transfected MDA-MB-231 cells with non-degradable β-catenin or treated with 5ng/ml human 
recombinant Tgf-β1 and incubated with 0.8μM actinomycin D to halt transcription.  Following 
actinomycin D treatment, we found that neither Tgf-β nor β-catenin alone or in combination 
rescued PTHrP mRNA expression over the course of the experiment (Figure 19B).  When we 
looked at select individual time-points, we found that a combination of recombinant Tgf-β and 
β-catenin over-expression significantly stabilized PTHrP mRNA, but when we conducted the  
 Figure 19.  Wnt signaling and Tgf
MDA-MB-231 cells transfected with non
harvested for Q-PCR.  Plot points indicate average GLI2 or (B) PTHrP mRNA expression 
normalized to 18S as a percentage of zero hour mean
trend of mRNA expression (n=3/plot point).  Values = mean ± standard error, and p
determined using unpaired t
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linear regression analyses, these data were no longer significant.  Therefore, the up-regulation 
of PTHrP mRNA expression that we observe downstream of enhanced Tgf-β and Wnt signaling is 
likely due primarily to an alteration in Gli2 and PTHrP transcription.     
Our data further supports the idea that Tgf-β signaling is important at the transcription 
level, and to that end, also introduces the idea that β-catenin is a PTHrP transcription regulator.  
Whether these effects are strictly through GLI2 mRNA expression, or rely on another 
mechanism, is unclear.  Recent data has suggested that PTHrP peptides may in fact stimulate β-
catenin in osteocytes (terminally differentiated osteoblasts) (272), and our data does not rule 
out the possibility that an autocrine signaling loop exists in osteolytic breast tumor cells.  In an 
effort to address previously published data, we did in fact examine Wnt signaling ligand 
expression by RT-PCR analysis.  MDA-MB-231 cells do not express most of the Wnt ligands, but 
surprisingly, none of the Wnt ligands we examined were elevated on the stiffer substrate, and 
several actually appeared to decrease slightly on TCPS (data not shown).  Indeed, it is quite 
conceivable that bone stiffness may be the ultimate regulator which initiates and activates Gli2 
and PTHrP through mechanotransduction (97), and that β-catenin is turned on secondary to 
these events, perhaps through its well-established association with E-cadherin (273) or 
interactions with the Src family kinases.  Unfortunately, studies examining the timing of these 
mechanisms in establishing and maintaining tumor-induced bone disease remain limited by 
both imaging techniques and molecular models of breast cancer metastasis to bone.  
Wnt and Tgf-β co-regulation of the GLI2 promoter 
There is ample evidence that the Tgf-β and Wnt signaling pathways crosstalk, both 
during development (274) and in cancer cells (275).  To this end, we examined the inter-
dependence of Wnt and Tgf-β signaling on GLI2 promoter activity using a construct in which the 
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TBE (mTCF) or SBE (mSmad) located within the GLI2 promoter has been mutated (60).  MDA-
MB-231 cells were transiently co-transfected with a GLI2 WT, mSmad, or mTCF promoter 
construct and Smad3 or β-catenin and harvested for luciferase assay analyses.  We found that β-
catenin stimulated GLI2 promoter activity when the SBE was mutated (Figure 20A), but Smad3 
activated the GLI2 promoter to a much lesser extent when the TBE was mutated (Figure 20B).  
These data indicate that Tgf-β signaling has some dependence on Wnt signaling for full Gli2 
regulation, but that Wnt signaling may not require active Tgf-β signaling to stimulate Gli2 
activity. 
Conclusions 
Our data indicate that there is a strong role for β-catenin regulation of GLI2 gene 
expression downstream of Wnt signaling in osteolytic tumor cells, and furthermore, that Wnt 
signaling is influenced by the rigidity of bone.  It is that stiffness plays a critical role in the early 
stages of tumor-induced bone disease through mechanotransduction and downstream Wnt and 
TGF-β signaling regulation, but does not affect tumor cell homing to bone, since the physical 
microenvironment is required for activation of mechanostransduction pathways.  These data 
provide further insight into the regulation of key players in osteolytic bone destruction, and may 
be important when considering novel therapeutic targets for use in breast tumor-induced bone 
disease. 
Importantly, we are hesitant to support the Wnt signaling pathway as a clinical target in 
blocking tumor-induced bone disease due to its critical role in osteoblast differentiation and 
protective effects in bone (126).  However, most pharmacological interventions for blocking 
breast tumor metastases and growth in bone are limited by their catabolic effects on bone, and 
are therefore coupled with adjuvant bisphosphonates (276), which inhibit osteoclast resorption, 
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or more recently denosumab (277), which targets RANKL in bone.   Despite its potential negative 
effects on bone, targeting the Wnt signaling pathway in bone metastases may be beneficial 
when combined with a bone protective adjuvant therapy. 
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Gli2 inhibition blocks tumor-induced bone disease 
Introduction 
 Gli2 up-regulation is a significant component of PTHrP-mediated bone destruction in 
breast tumor metastasis to bone (36), and our data presented here indicate that the Tgf-β and 
Wnt signaling pathways are potential targets in blocking Gli2 and PTHrP-induced osteolysis; 
however, both of these pathways impart a significant contribution to tumorigenesis at the 
primary tumor site, which may compromise their effectiveness in patients with metastatic 
disease.  Although Gli2 is expressed ubiquitously throughout development and participates in 
patterning, etc., it is effectively shut off after puberty.  Thus targeting Gli2 directly may be a 
more promising approach to block osteolysis with minimal toxicity in humans. 
 We therefore hypothesized that inhibiting Gli2 through genetic or pharmacological 
approaches in a mouse model of breast cancer metastasis to bone would result in decreased 
osteolysis.  For the genetic studies, MDA-MB-231 cells stably transfected with the Gli2-Rep 
construct, as described in an earlier section, were used in a mouse model of breast cancer 
metastasis to bone.  The Gli-Antagonist (GANT) compounds, which inhibit Gli function 
irrespective of the mutation leading to the activation of Gli (24), were used to pharmacologically 
inhibit Gli2 signaling.  These compounds were identified in a cell-cased screen for inhibitors of 
Gli1, so they lack some specificity for Gli2.  Perhaps due to limited availability as a result of lack 
of large-scale synthesis of these compounds, they have been tested in relatively few models (62, 
278). 
Gli2 repression inhibits tumor-mediated osteolytic bone destruction 
 In order to determine if blocking Gli2 activity could indeed inhibit tumor-induced 
osteolysis, we inoculated pooled MDA-MB-231-Gli2-Rep and MDA-MB-231-cntrl cells into 4-
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week old athymic female nude mice via the left cardiac ventricle. After 4 weeks, extensive 
osteolytic lesions were visible by radiography in the femora/tibiae of the control mice.  In 
contrast, the Gli2-Rep mice had either small or undetectable lesions (Figure 21A).  
Quantification of lesion number and size on radiographs indicated that mice bearing MDA-MB-
231-Gli2-Rep tumor cells had significantly fewer and smaller lytic lesions than the mice bearing 
control cells (Figure 21B&C).  Similar results were obtained for mice inoculated with Gli2-Rep 
transfected cells derived from single cell clones (Figure 22).  
In addition to radiographic analyses, tibiae were examined by ex vivo microCT. There 
was a significant decrease in trabecular bone volume in the MDA-MB-231-cntrl inoculated mice 
compared to the MDA-MB-231-Gli2-Rep inoculated mice (Figure 23A), although there were no 
other significant changes in microCT parameters such as trabecular number, trabecular 
thickness, or connectivity density (Figure 23B-D).  Bone volume of mice inoculated with MDA-
MB-231-Gli2-Rep cells was not significantly different from non-tumor bearing age- and sex-
matched mice (BV/TV approx. 0.0448-.1518).  These data indicate that Gli2 inhibition in MDA-
MB-231 cells decreased the ability of the tumor cells to induce bone destruction. 
Consistent with disrupting TGF-β induced propagation of tumor-induced osteolysis, 
histomorphometric analyses of the tibiae revealed a significant decrease in tumor burden in 
Gli2-Rep tumor bearing mice relative to empty-vector control tumor-bearing mice (Figure 23E), 
and this was accompanied by a reduction in detectable PTHrP protein expression identified by 
immunohistochemistry (Figure 23F). 
Interestingly, we observed a decrease in tumor burden at sites of bone metastases in 
the Gli2-Rep intracardiac model, although tumor growth was unaltered in the Gli2-Rep 
orthotopic mammary fat pad model as shown in Figure 11C.  Since our previous data indicate  
 Figure 21.  Gli2-Rep blocks tumor
Gli2-Rep (n=7) or MDA-MB
radiographically weekly.  (a)  Faxitron images depict fewer lesions in mice inoculated with MDA
MB-231-Gli2-Rep cells.  There was a significant reduction
and average lesion area/mouse (c), as measured by region of interest (ROI) analysis.  Values = 
mean ± standard error, and p
0.01, ***p<0.001. 
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-induced bone disease.  Mice inoculated with MDA
-231-cntrl (n=10) cells via intracardiac injection were imaged 
 in average lesion number/mouse (b) 
-values were determined using unpaired t-test.  *p< 0.05, **p< 
 
-MB-231-
-
 Figure 22.  Gli2-Rep reduces tumor
cells.  MDA-MB-231 cells transfected with Gli2
single cell limiting dilutions, clonally selected for antibiotic resistance (400µg/ml 
selection), and inoculated into female, athymic nude mice via intracardiac injection (n=10, 
control; n=9, Gli2-Rep).  (a)  Faxitron images depict decreased osteolysis in mice inoculated with 
either clone 1 or clone 2 of the MDA
cntrl inoculated mice.  Quantification of these images using Metamorph shows a significant 
reduction in (b) average lesion number/mouse and (c) average lesion area/mouse.  Values = 
mean ± standard error, and p
0.01, ***p<0.001. 
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G418 
-MB-231-
 Figure 23.  Gli2-Rep reduces osteolysis and tumor burden.
analyses indicate a significant reduction in osteolysis in MDA
(n=7 tibiae) compared to MDA
(Scanco) analyses do not indicate any significant dif
beyond bone volume in MDA
MB-231-Cntrl inoculated mice (n=10 tibiae).  (B) Trabecular number, (C) Trabecular thickness, 
and (D) Connectivity density.  His
show (E) significant inhibition of tumor burden in MDA
(F) decreased immunohistochemical staining for PTHrP in sections from MDA
mice.  The black bar on the histological sections represents a length of 500µM. Values = mean ± 
standard error, and p-values were determined using unpaired t
***p<0.001. 
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that Tgf-β at least in part regulates Gli2 signaling, we reason that the observed decrease in 
tumor growth was caused by indirect blockade of Tgf-β stimulation of PTHrP, and overall 
blockade of the vicious cycle.  Our in vitro studies demonstrated that Gli2 is in fact required for 
Tgf-β to increase PTHrP expression, suggesting that when Gli2 is not activated, Tgf-β in the bone 
matrix will no longer have a stimulatory effect on PTHrP secretion from breast cancer tumor 
cells and consequently tumor cell growth and bone resorption will be inhibited.   
GANT inhibits PTHrP expression but not osteolysis 
 The GANT compounds (GANT58 and GANT61) were initially discovered in a cell-based 
screen to find inhibitors of the Hh transcription factor Gli1, which is known to be important in 
tumorigenesis at the primary site of disease (62); however, due to the homology between Gli1 
and Gli2, these compounds effectively block the function of both molecules.  Both compounds 
are believed to inhibit Hh downstream of Smo by causing a conformational change in nuclear Gli 
which compromises DNA binding (62). 
In an effort to block Gli2 signaling in osteolytic tumor cells, we treated MDA-MB-231 
cells with 10μmol GANT58 and found that it significantly blocked PTHrP mRNA expression in 
vitro (Figure 24A), and similar to our Gli2-Rep data, found that GANT58 had no effect on tumor 
cell growth at the primary site when MDA-MB-231 cells were inoculated into the mammary fat 
pad (Figure 24B). 
Since GANT 58 successfully reduced PTHrP expression in vitro, we tested its 
effectiveness in a mouse model of breast cancer metastasis to bone, where we inoculated 4-
week old athymic nude mice with MDA-MB-231-GFP cells via intracardiac injection and treated 
mice with 25mg/kg/day of GANT58 by i.p. injection.  When we examined GANT58 effects on 
tumor burden, we found that although GANT58 treatment trended toward a decrease in tumor 
 Figure 24.  GANT58 reduces PTHrP expression but does not alter tumor growth 
MDA-MB-231 cells were treated with 10μmol GANT58 for 24 hours and harvested for RNA.  (B)  
4-week old athymic nude mice were inoculated with 1×10
mammary fat pad, treated with 25mg/kg/day GANT58 (n=6) or PEG (n=8) and allowed to grow 
for 23 days.  Tumor size was determined by caliper measurement throughout experiment.  
Values = mean ± standard error, and p
**p< 0.01, ***p<0.001. 
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burden by histomorphometric analyses (Figure 25A), tumor cell fluorescence revealed no 
significant changes in tumor burden (Figure 25B).  Analyses of GANT58 treatment on bone 
volume in the same tumor bearing animals indicated that although GANT58 treatment trended 
toward increased bone volume and trabecular number by ex vivo microCT (Figure 25F&G), it did 
not did not alter bone volume as measured by histomorphometry (Figure 25C), nor did it affect 
the microCT parameters of trabecular spacing, trabecular thickness (Figure 25H&I), or lesion 
area or lesion number as measured by Faxitron analyses (Figure 25D&E).  Similar negative 
results were found when mice were inoculated with MDA-MB-231 cells directly into the tibia 
(Figure 26), and when treated with GANT61 (data not shown). 
Although Gli proteins are not expressed in adult mice, the unanticipated results from 
the GANT58 intracardiac and intratibial studies prompted us to test GANT58 effects on normal 
bone modeling.  When we treated normal mice with 25mg/kg/day of GANT58, we found that 
GANT58 treatment resulted in decreased bone volume and trabecular number, and increased 
trabecular spacing by microCT analyses (Figure 27A-C), but did not affect trabecular thickness 
(Figure 27D).  In order to determine if the data was due to an increase in osteoclast number, 
histological sections were stained for TRAP positive osteoclasts, where we found that neither 
osteoclast number nor osteoclast surface/bone surface were elevated (Figure 27E&F).  Since 
GANT58 disrupts downstream Hh signaling, which is important for growth plate regulation 
during development (279), and our breast tumor model uses 4-week old mice, we tested 
whether GANT58 affects the overall height or organization of the growth plate.  We found that 
GANT58 treatment did not affect the overall height of the growth plate (Figure 27G), but 
significantly reduced the size of the proliferation zone (Figure 27H), and disrupted its 
organization as seen in Figure 28I.  
 Figure 25.  GANT58 does not block osteolysis as measured b
athymic nude mice were inoculated with 1×10
treated with 25mg/kg/day GANT58 (n=11) or PEG (n=13), and sacrificed after 4 weeks, with 
imaging throughout. (A) Histomorphometric 
decreased tumor burden with GANT58 treatment.  (B) Tumor cell fluorescence imaging by 
Maestro shows no change in tumor burden.  (C)  Histomorphometric analyses show no change 
in bone volume.  (D,E) Faxit
GANT58 treatment.  (F-I) 
volume (F) and Tb. Number (G), but no significant changes were detected in any parameters 
with any imaging modality. 
using unpaired t-test.   
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  4-week old 
 Figure 26.  GANT58 does not alter bone volume or tumor burden in the mouse intratibial 
model.  4-week old athymic nude mice were inoculated with 1×10
into the tibia, treated with 25mg/kg/day GANT58 (n=7) or PEG (n=5) and
weeks, with imaging throughout.  (A) Histomorphometry analyses reveal that GANT58 
treatment slightly prevented osteolysis in the tumor limb and had no affect on the control limb.  
Neither of the results were significant.  (B)  Histomorp
did not decrease tumor burden, although there was a slight trend toward decreasead tumor 
burden with GANT58 treatment. (C) MicroCT analysis of the tumor bearing limb showed that 
PEG treated mice had lower bone volume tha
significant. Values = mean ± standard error, and p
test. 
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 Figure 27.  GANT58 decreases bone volume through disruption of the growth plate.
old athymic nude mice were treated with GANT58 (n=4) or PEG (n=5) for 4 weeks until sacrifice.  
(A)  MicroCT analyses reveal that GANT58 treatment significantly reduced bone volume, (B) Tb. 
Number, and (C) Tb. Spacing, but did not affect (D) Tb. thickness.  Histomorphomet
show that (E) Oc number and (F) surface area were unaffected by GANT58 treatment, and that 
(G) the height of the growth plate was not altered.  (H, I)  Further analysis of the growth plate 
shows that the proliferating zone of chondrocytes was 
Values = mean ± standard error, and p
**p< 0.01, ***p<0.001. 
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We believe that this phenotype can be largely attributed to limitations of the tumor 
model, in that 4-week old mice with an open growth plate are required for efficient tumor take.  
Gli2 is essential for normal growth plate development, and bones harvested from Gli2-/- 
embryos show decreased Ihh, Ptch, and PTHrP expression (59), which fits well with the observed 
reduction in the size of the growth plate proliferating zone after GANT58 treatment and also 
suggests that the significant decrease in bone volume occurs because there is less foundation 
for bone being made in the presence of GANT58.  In addition to the observed effects of GANT 
treatment on chondrocyte maturation, disruption of downstream Ihh signaling by GANT may 
also elicit an effect on osteoblast differentiation.  Indeed, Ihh produced by prehypertrophic 
chondrocytes, in addition to signaling back to proliferating chondrocytes, also signals to the 
perichondrium to stimulate osteoblast differentiation (279).  This correlates well with our Gli2-
Rep data, in which we disrupted Gli signaling in the tumor cells only and observed a reduction in 
tumor burden and osteolysis. Therefore, we believe that Gli2 is still an effective target, but that 
the limitations of our tumor model make this difficult to explore therapeutically.  We hope to 
develop a tumor model in the future which will allow us to test the effects of GANT in a mouse 
model of breast cancer metastasis to bone in which the growth plate is closed. 
Conclusions 
The inhibition of bone destruction and tumor growth observed in the Gli2-Rep tumor 
bearing mice identifies Gli2 as a promising target for developing therapeutic approaches in the 
prevention and treatment of tumor-induced bone disease.  Postnatal expression of Gli2 is 
primarily limited to the growth plate (59) and the hair follicle (280, 281), making Gli2 an ideal 
clinical target with low potential for significant off target effects in adult patients.   
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This work demonstrates that Gli2 genetic inhibition reduces tumor growth and bone 
destruction, suggesting that targeting Gli2 may be a valid approach to inhibit bone metastases; 
however, our GANT in vivo results indicate that inhibiting Gli signaling in adolescents would 
reduce the anti-osteolytic effect of Gli inhibition.  Therefore, we would only recommend using 
Gli inhibitors in adults, where we believe that osteolysis and tumor burden would be reduced.  
This seems quite reasonable clinically, since breast cancer does not affect pre-adolescents. 
Accordingly, the guanosine nucleotide 6-TG is used clinically in leukemia patients and 
has been shown to effectively block osteolysis and reduce tumor burden in a mouse model of 
breast cancer metastasis to bone (27).  Since 6-TG was not reported to affect the growth plate in 
these mice, we investigated whether 6-TG inhibition of PTHrP is mediated through Gli2, and 
perhaps preferentially affects tumor cells since they are rapidly dividing.  These data are 
presented in the following section.     
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6-Thioguanine inhibition of PTHrP is mediated through Gli2 
Introduction 
The release of PTHrP into the tumor-bone micro-environment contributes to increased 
osteoclastogenesis and the excessive release of active Tgf-β at the site of skeletal metastasis.  
Our group has previously demonstrated that GLI2 overexpression in osteolytic breast cancer 
cells increases osteolysis in vivo (36), and here we have shown that transfection with Gli2-Rep 
inhibits PTHrP mRNA expression in vitro and in vivo. In addition, others have shown that PTHrP 
inhibition by neutralizing antibody prevents tumor-induced bone destruction in a murine model 
of breast cancer metastasis to bone (28). 
Guanosine metabolites have been clinically utilized for the treatment of acute leukemia, 
where the purine analogs incorporate into DNA and disrupt its replication and subsequent 
cellular proliferation (224), resulting in a modest antitumor effect.  6-Thioguanine (6-TG) was 
initially identified during a cell-based screen for compounds that inhibit PTHrP promoter 
activation, and has been shown to specifically inhibit PTHrP expression at low doses and with 
little cytotoxicity (27).  6-TG has also been shown to inhibit PTHrP activity in human breast 
cancer cells in vitro and tumor growth and osteolysis in vivo in a murine model of breast cancer 
metastasis to bone (27); however, the mechanism through which 6-TG inhibits PTHrP remains 
unknown. 
Based on these data, we hypothesized that the inhibitory effects of 6-TG on PTHrP occur 
in a Gli2-dependent manner.  In this study, we treated human osteolytic MDA-MB-231 breast 
cancer cells and human RWGT2 squamous-cell lung carcinoma cells with 6-TG and examined 
GLI2 mRNA transcription and stability by Q-PCR.  In addition, we transfected osteolytic breast 
cancer cells with a GLI2 promoter construct and examined the ability of 6-TG to directly inhibit 
116 
 
GLI2 promoter activity.  Lastly, GLI2 was constitutively expressed under the CMV promoter to 
block the inhibitory effect of 6-TG on PTHrP mRNA expression.   
Low doses of 6-TG do not inhibit cell proliferation 
 It has previously been shown that low doses of 6-TG specifically inhibit PTHrP in tumor 
cells, but do not alter tumor growth in vivo (27).  In order to more directly examine the effect of 
low-dose 6-TG treatment on tumor cell growth, we determined whether the general cytotoxic 
effects of 6-TG were abolished at low-dose treatment in vitro.  In order to determine the effect 
of low dose 6-TG on cell proliferation, MDA-MB-231 or RWGT2 cells were treated with 100 µmol 
6-TG and examined for changes in cellular metabolism via MTS assay.  We found that at low 
doses, 6-TG does not inhibit tumor cell growth of MDA-MB-231 (Figure 28A) or RWGT2 cells 
(Figure 28B), indicating that the effects of 6-TG on PTHrP are not due to changes in cell 
proliferation.  
6-TG exhibits inhibitory effects on GLI2 mRNA and protein expression 
We have shown here that both RWGT2 and MDA-MB-231 cells express detectable levels 
of GLI2, and that TMC23 cells express GLI2 and the Hh signaling receptors PTCH and SMO.   Since 
it is well-established that Gli2 regulates PTHrP in some osteolytic breast cancer cells (36, 61), we 
rationalized that 6-TG may therefore inhibit PTHrP through Gli2 regulation.   To determine the 
effect of 6-TG on GLI2 and PTHrP mRNA expression in tumor cells, we treated MDA-MB-231 
human breast cancer cells, RWGT2 human squamous-cell lung carcinoma cells, and control 
TMC23 proliferating chondrocytes with 100 µmol 6-TG and harvested cells after 24 or 48 hours 
for RNA, which was reverse transcribed for Q-PCR.  We found that 6-TG significantly inhibited 
expression of GLI2 and PTHrP mRNA in MDA-MB-231 cells at both 24 and 48 hours post- 
treatment, and modestly inhibited these in RWGT2 and control TMC23 cells (Figure 29A&B), and  
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these effects were observed as early as 4 hours post-treatment in MDA-MB-231 cells (Figure 
29C).  To determine whether 6-TG also has inhibitory effects at the protein level, we analyzed 
MDA-MB-231 and RWGT2 cell lysates by Western blot for Gli2 protein expression.  We found 
that 6-TG treatment reduced Gli2 protein expression (Figure 29D) in both MDA-MB-231 and 
RWGT2 cells, indicating that 6-TG functions at multiple levels to inhibit Gli2 expression. 
6-TG does not affect mRNA stability at low doses 
Since previous reports show that 6-TG inhibits steady-state PTHrP mRNA expression at 
later time points of incubation (27) and our data suggest that 6-TG inhibits GLI2 mRNA 
expression, we also determined its effects on mRNA stability.  MDA-MB-231 and RWGT2 cells 
were treated with the transcriptional inhibitor actinomycin D as previously described (282) two 
hours post-6-TG treatment and cells were harvested every two hours for RNA and subsequent 
reverse transcription for real-time PCR.  We found that 6-TG treatment had no effect on GLI2 or 
PTHrP mRNA degradation in either MDA-MB-231 breast cancer cells (Figure 30A) or RWGT2 
squamous-cell lung carcinoma cells (Figure 30B).  Indeed, the data indicated that there may in 
fact be a slight trend towards PTHrP and GLI2 mRNA stabilization in the presence of 6-TG.  
Although the effects of actinomycin D in blocking transcription are not specific for GLI2, these 
data exclude the possibility that 6-TG blocks expression of Gli2 and PTHrP through a post-
transcriptional effect, and strongly suggest that the specific inhibitory effect of 6-TG on Gli2 and 
PTHrP indeed occurs at the transcriptional level. 
Previous work by our group indicated that 6-TG affects steady-state PTHrP mRNA 
expression (27); however, the data presented here suggest that GLI2 and PTHrP mRNA are not in 
fact de-stabilized in the presence of 6-TG, but rather that 6-TG treatment may cause a modest 
increase in GLI2 and PTHrP mRNA stability in MDA-MB-231 cells.  Despite this effect, PTHrP and  
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GLI2 mRNA expression levels are down-regulated in the presence of 6-TG, suggesting that 6-TG 
overcomes mRNA stabilization to dramatically inhibit transcription.  These data were surprising 
considering our group’s previously published data showing 6-TG stabilization of PTHrP mRNA 
(27), but we believe these differences stem from the techniques used in determining mRNA 
stability.  Differences may also be attributed to variance in time points, since our group 
previously focused on later time points (48 hours) for steady-state mRNA expression (27), and 
our studies here focus on earlier time points.    
6-TG directly reduces GLI2 promoter activity 
Since our work has demonstrated that 6-TG inhibits GLI2 expression and leads to PTHrP 
inhibition, we determined whether 6-TG directly regulates GLI2 promoter activity using a GLI2 
promoter construct (60).  MDA-MB-231 cells were transiently transfected with the GLI2 WT 
promoter construct and harvested for luciferase assay 24 hours following 1mmol 6-TG 
treatment.  We found that 6-TG significantly inhibited GLI2 promoter activity when compared to 
MDA-MB-231 cells expressing a control vector in both serum-free medium (Figure 31A) and in 
the presence of recombinant human Tgf-β1 (Figure 31B).  Recent reports have indicated that the 
GLI2 promoter contains a SMAD-binding element (SBE) and T-cell factor (TCF)-binding element 
(TBE), indicative of both Tgf-β and β-catenin signaling regulation of GLI2 transcription (60).  
Interestingly, 6-TG inhibited the GLI2 promoter even when the SBE or TBE was mutated (Figure 
31), suggesting that these elements are not essential for 6-TG regulation of GLI2.    
Circumventing the GLI2 promoter abrogates 6-TG inhibitory effect on PTHrP transcription 
In order to determine whether Gli2 acts upstream of PTHrP to elicit 6-TG inhibitory 
effects on transcription, we reasoned that the blockade of the GLI2 promoter should prevent 6- 
TG inhibition of PTHrP mRNA expression.  We therefore transfected MDA-MB-231 cells with a  
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GLI2 construct constitutively expressed under the CMV promoter.  Since we have shown that 6-
TG regulates GLI2 expression at the mRNA level, 6-TG treatment should affect endogenous GLI2, 
but will be unable to inhibit GLI2 expressed under a constitutive promoter such as CMV (Figure 
32A).  Therefore, constitutive expression of GLI2 should prevent the inhibitory effects of 6-TG on 
PTHrP expression that work through stimulation of the GLI2 promoter.  Following transfection 
with CMV-GLI2 and 6-TG treatment, we found that PTHrP mRNA expression was no longer 
affected by 6-TG in the MDA-MB-231 cells overexpressing GLI2 under control of the CMV 
promoter (Figure 32B).  
Conclusions 
While we have demonstrated that 6-TG targets GLI2 mRNA and protein expression, it 
remains unclear whether 6-TG directly targets GLI2, or if the effects of 6-TG on GLI2 are driven 
by signaling upstream of GLI2.  An essential role of GLI2 is regulating PTHrP expression and 
subsequent osteolysis by tumor cells, which underlines the importance of finding the 
mechanism through which GLI2 transcription is activated.  For example, our group and others 
have previously published that Tgf-β signaling plays a key regulatory role in GLI2 transactivation 
(60, 61, 114).  Our data presented in Figure 32A are in serum-free conditions, and do not contain 
excess human Tgf-β1, which can elevate GLI2 promoter activity above basal levels; however, 
when we repeated this experiment in the presence of recombinant human Tgf-β1, we saw 
similar results (Figure 31B), indicating that there are Tgf-β independent pathways regulating 
GLI2. 
Given the clinical success of 6-TG treatment in cancers such as leukemia, and that 6-TG 
appears to specifically inhibit Gli2 upstream of PTHrP, the use of 6-TG against tumor types in 
which GLI2 is up-regulated may be a potential therapeutic option.  GLI proteins have been 
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demonstrated to be up-regulated in a number of tumor types, including medulloblastoma and 
tumorigenesis (66).  However, due to the cytotoxic and off-target effects of 6-TG in the clinical 
setting, other groups are investigating alternative guanidine-related compounds (283).  Similar 
to 6-TG, these drugs are effective inhibitors of PTHrP, but the mechanism has not been 
investigated.  It is likely that these drugs work in part through Gli2 inhibition, similar to 6-TG.  
However, in vitro they appear more potent and possibly more specific to PTHrP (283). 
Taken together, our data indicate that low-dose 6-TG effects on PTHrP are driven at 
least in part though Gli2 inhibition, and are independent of tumor cell growth.  Therefore, Gli2 
inhibition by low-dose 6-TG may be a novel therapy in cancer patients expressing elevated levels 
of Gli proteins. 
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CHAPTER IV 
DISCUSSION AND SIGNIFICANCE 
Despite advances in the treatment of tumor-induced bone disease, primarily through 
the introduction of anti-resorptives such as bisphosphonates and denosumab, significant 
advancements are still needed to alter the course of the disease from terminal to chronic, or to 
eradicate it altogether.  In order to advance the field, improvements in both our technologies 
and our understanding of interactions between the tumor cells and the bone micro-
environment are critical.   
Advances in imaging technology 
The data presented here indicate that there are still advancements to be made in 
monitoring tumor and bone interactions through multiple imaging modalities.  Although we 
have frequently relied on Faxitron and fluorescence imaging to monitor tumor cells and 
resulting bone destruction in the past, our data indicate that there are more effective methods 
for monitoring these interactions such as through in vivo microCT, PET, or SPECT.  The largest 
obstacle to overcome with these technologies is the low throughput and associated costliness.  
The low efficiency of new imaging technologies like in vivo microCT is likely to be improved 
rapidly as the importance of imaging modalities that can detect bone destruction earlier and 
with greater sensitivity than current standards becomes more appreciated.  In addition to 
computed tomography, NIR technology holds great promise as a tool for monitoring tumor 
growth in bone and the localization of proteins to sites of skeletal metastasis (164-166).  
Additional studies by our group have utilized NIR-tagged antibody to monitor drug distribution 
in tumor metastasis models, where uptake of the antibody in bone indicates more rapid 
turnover and correlates with tumor burden (unpublished data). 
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Tgf-β signaling in the vicious cycle 
Our understanding of the molecular mechanisms which drive tumor cell growth in bone 
is as important as our ability to visualize tumor-bone interactions.  Our data indicate that in 
breast tumor cells that cause osteolysis, factors which regulate the production of osteolytic 
molecules are essential for tumor-induced bone destruction.  Specifically, our data indicate that 
Tgf-β regulates the transcription factor GLI2 in osteolytic tumor cells, instead of the Hh signaling 
pathway, which regulates Gli2 production during development.  This novel finding is of particaul 
importance to pre-clinical studies, since drug companies are actively pursuing cyclopamine 
analogues as inhibitors of Hh signaling and the Gli proteins in particular.  Our data indicate that 
although these analogues may be less toxic than cyclopamine, they will likely be ineffective in 
blocking breast tumor-induced osteolysis.  Tgf-β stimulation of Gli2 enhances PTHrP production 
and the resulting bone destruction, and accordingly, Gli2 inhibition reduces osteolysis.  These 
data confirm the previously published finding that GLI2 is regulated in part by a Smad binding 
element within the promoter (60).  The mineralized bone matrix is a significant reservoir for Tgf-
β, which is released in its active form upon bone resorption by activated osteoclasts (26); 
however, the timing of Tgf-β signaling in promoting tumor-induced bone disease has been 
debated since copious amounts of active Tgf-β will likely not be released from the bone matrix 
until the tumor cells are well established in bone and had adequate time to activate 
RANK/RANKL signaling and enhance osteoclastogenesis.   
Tumor-matrix interactions 
It is currently unknown whether osteolytic tumor cells up-regulate the expression of Gli2 
prior to, during the metastatic cascade, or after establishment in bone, but our group has 
observed that the physical bone micro-environment plays a significant role in activating GLI2 
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and PTHrP transcription (97), and our data presented here indicate that bone stiffness may also 
activate Wnt signaling, which has been linked to mechanotransduction pathways like Src (255-
258).  Although it is difficult to distinguish the timing of these pathways in the establishment of 
tumor-induced bone disease, our data suggest that when tumor cells metastasize to bone, they 
sense the physical stiffness of the bone micro-environment, which may or may not be through 
direct interactions between the tumor cells and bone matrix.  Histology indicates that tumor 
cells may reside in direct contact with the bone matrix in certain planes, but it is difficult to 
determine whether this is an artifact of histological processing or a biological phenomenon.  
Even if tumor cells do not come in direct contact with the bone but rather come in physical 
contact with bone lining cells, we believe that tumor cells are still able to sense bone stiffness, 
since our in vitro data indicates that there is a direct effect of matrix stiffness on tumor cell gene 
expression.  Whether bone stroma such as osteoblasts or fibroblasts contribute to tumor cells 
sensing bone stiffness in vivo remains to be determined.   
Our group has previously shown that increasing matrix stiffness up-regulates expression 
of the Tgf-β1 ligand and activates Tgf-β signaling as measured by 3TP-lux (97), and our data 
presented here indicate that Wnt signaling is also activated with increased matrix stiffness, as 
measured by TOPFlash activation (Figure 14A) and PCR array (Table 1).  This was further 
supported by enhanced nuclear localization of β-catenin when tumor cells were seeded onto 
stiff TCPS (Figure 14B).  Wnt signaling has been previously shown to crosstalk with 
mechanotransduction pathways (257-260), and our data suggest that this activation may also 
trigger downstream effects on Gli2 and PTHrP.  This also opens up the possibility that Src 
signaling may regulate Gli2 and PTHrP.  In combination, these data suggest that when tumor 
cells sense the stiffness of bone, they activate both the Tgf-β and Wnt signaling pathways in 
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osteolytic tumor cells, which in turn activate GLI2 transcription, as indicated by our promoter 
and mRNA expression data (Figures 15, 16, and 20) in MDA-MB-231 cells.   
Proposed timing of the vicious cycle 
We propose that Tgf-β signaling is important early in the vicious cycle for the activation 
of Gli2 and PTHrP, and late in the vicious cycle, to maintain this up-regulation and tumor cell 
proliferation.  It is also likely that the stiffness of bone regulates the initial Tgf-β response, but it 
is the continuous release of active Tgf-β from the mineralized bone matrix which maintains the 
vicious cycle, since the rigidity of bone will diminish as the cycle continues and bone is degraded.  
Accordingly, we propose that Wnt signaling is also important early in the vicious cycle for 
complete activation of GLI2 transcription, but that the copious amounts of Tgf-β present in the 
tumor-bone micro-environment late in the vicious cycle are sufficient to continue Gli2 
expression and PTHrP production.  As bone degrades and its rigidity is diminished with 
decreasing bone volume, the mechanotransduction pathways that crosstalk with Wnt signaling 
through Src and β-catenin interactions and with Tgf-β signaling through ROCK are likely also 
reduced.  At this point late in the vicious cycle, the role of the surrounding stroma may become 
increasingly important (Figure 33).  Indeed, data from our group suggests that both normal and 
cancer-associated fibroblasts can enhance Gli2 and PTHrP production in MDA-MB-231 cells 
through an unknown soluble factor.  Conditioned media harvested from a number of primary 
human fibroblast cultures were found to increase GLI2 and PTHrP mRNA expression, and MDA-
MB-231 cells co-inoculated with primary human fibroblasts directly into the tibia resulted in 
enhanced bone destruction (unpublished data).  These effects may be mediated through Tgf-β, 
Wnt signaling, or both.  Further studies are required to determine fibroblast contribution to 
osteolysis.  It is important to note that these effects would be separate from stiffness activation  
 Figure 33.  Proposed timing of stiffness, Tgf
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of Wnt or Tgf-β signaling activity since increasing rigidity alone is sufficient to enhance both of 
these signaling pathways. 
Inhibiting Tgf-β/Wnt signaling in osteolysis 
In addition to its extensive role in tumor-induced bone disease, Tgf-β signaling is 
important for maintenance of normal bone homeostasis, which is evidenced by mouse models 
of TGF-β blockade which result in enhanced bone mineral density and bone volume due to 
increased osteoblast and decreased osteoclast numbers (12, 13).  Unpublished data from our 
group (Biswas et al., submitted) also suggests that inhibition of Tgf-β signaling may be beneficial 
in blocking breast tumor-induced bone disease.  Our in vitro data supports these findings in 
preclinical models.  However, our most accurate mouse model available for studying human 
tumor-induced bone disease relies on intracardiac injection and does not take into account the 
biphasic effect of Tgf-β on the primary tumor.  Patients with residual tumor at the primary site 
could experience increased metastasis with Tgf-β inhibition, due to the protective effects of Tgf-
β in tumorigenesis (216).  Therefore, Tgf-β blockade would only be recommended in patients in 
whom the primary tumor has been completely removed, as in such cases where the patient has 
undergone a mastectomy. 
Similarly, there are caveats to consider in blocking Wnt signaling in osteolysis, namely 
the anabolic effects of Wnt signaling through osteoblast differentiation.  LRP5-/- mice exhibit a 
low bone mass phenotype and disrupted preosteoblast differentiation (120), suggesting that 
Wnt inhibition could have catabolic effects in bone metastasis patients.  Furthermore, our in 
vitro data do not directly indicate that Wnt inhibition would inhibit Gli2 or PTHrP production, 
since blocking Wnt through small molecule antagonists was ineffective.  It remains unclear 
whether this was due to low endogenous levels of β-catenin in the MDA-MB-231 cells or 
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because Tgf-β is compensatory, but it is unlikely to be the latter since we have tested TGF-β 
activity when MDA-MB-231 cells are treated with a Wnt inhibitor and observe no detectable 
changes in 3TP-lux activation (data not shown).   If further studies warrant the use of Wnt 
signaling in vivo to block tumor-induced osteolysis, it would need to also be tested with an anti-
resorptive drug such as a bisphosphonate to counteract the catabolic effect it may have on 
bone.  
Gli inhibition and tumor-induced bone destruction 
There are a number of complications associated with Tgf-β and Wnt inhibition for the 
treatment of osteolysis, but our data indicate that Gli2 is an effective target in blocking tumor-
induced bone disease, particularly based on our evidence from the Gli2-Rep construct in which 
Gli2 is preferentially repressed in tumor cells only (Figures 21-23).  Due to limitations in our 
tumor model, we were unable to repeat these data using the small molecule inhibitor GANT58, 
but we were able to show that 6-TG, which at low concentrations specifically inhibits PTHrP (27), 
also inhibits GLI2 activity.  These data are still somewhat puzzling since the mouse tumor model 
using 4-week old mice was used in both the GANT58 studies and the previously published 6-TG 
studies (27), but 6-TG was not reported to have any detrimental effects on bone volume or the 
growth plate.  We believe these results may be attributed to the targeting of 6-TG to tumor 
cells, since presumably a chemotherapeutic agent such as 6-TG would likely be incorporated 
much faster and more efficiently into rapidly dividing tumor cells than into chondrocytes of the 
growth plate in late stages of development.  Conversely, GANT58 appears to show no specificity 
to tumor cells over any other cell expressing Gli1 or Gli2.  The differential effect could also be 
due to 6-TG specificity for Gli2 in particular, whereas GANT58 inhibits both Gli1 and Gli2.  
Furthermore, Gli1 may compensate for the loss of Gli2 in the growth plate during 6-TG 
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treatment.  Therefore, we still conclude that Gli2 may be an effective target in tumor-induced 
osteolysis, but that better inhibitors are needed.  Fortunately, interest still lies in developing 
inhibitors against the Gli proteins due to their up-regulation in numerous tumor types (66).  For 
example the E. agallocha compounds which were extracted from Japanese herbals are currently 
under investigation as Gli inhibitors in pancreatic and prostate cancer cells (63), and our group 
intends to test these compounds in primary breast cancer and breast tumor metastasis to bone, 
as well investigating any skeletal effects on normal mice. 
Taken together, our data indicate that the stiffness of bone activates both Tgf-β and 
Wnt signaling to up-regulate GLI2 transcription early in the vicious cycle, and that Gli2 may 
therefore be a more specific therapeutic target than Tgf-β or Wnt signaling in blocking tumor-
induced bone disease.  We believe that patients suffering from tumors in which the Gli proteins 
are up-regulated could benefit significantly from Gli inhibition, and studies will continue in an 
effort to find accurate preclinical models which accurately reflect the human condition.    In the 
future, our advances in imaging technology will allow us to better explore Gli2 as a clinical target 
and more accurately examine the signaling pathways that regulate Gli2.  
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